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Thank you for articles  
on children and microbes
What a wonderful recent edi-
tion of Yale Medicine [Spring 
2015]! Two articles particularly 
affected my pediatric mindset 
and got me thinking (a little 
harder to do at my age):  
“How children rebound from 
their worst nightmares” and  
“A bug’s journey.”
I have been concerned about 
so many children in our prosper-
ous country receiving little “par-
enting” or supervision. Surrogate 
“caregivers,” in my mind, just 
can’t cut it. Without instruction 
or modeling, a child doesn’t just 
automatically metamorphose 
into a good kid that has no need 
for behavior-modifying drugs. 
Contrast the prosperous with the 
opposite—occupants of a Syrian 
refugee camp.
I witnessed penicillin as 
both a miraculous germ killer 
and as the ineffective antibi-
otic it became for strains of 
Staphylococcus aureus: first 
as a Navy hospital corpsman 
treating the “sins” of returning 
Marines with aqueous penicil-
lin delivered by a syringe with 
a huge needle on one end; and 
later, witnessing the discov-
ery that newborns with Staph 
pneumonia were dying in spite 
of penicillin’s being adminis-
tered. As time progressed, I 
realized that I needed more 
knowledge of how our immune 
systems work and how  
pathogens could outsmart  
us. I attended seminars on 
immunology that, I have to 
admit, were over my head.  
If only I had read this article 
40 (maybe 50) years ago. I loved 
the teaching of the difference 
between RNA viruses and DNA 
bacteria in the context of their 
mutation “mistakes” or other 
means of change.
A very interesting edition. 
Thank you.
Ralph K. Campbell, M.D. ’50 
Polson, Montana
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  From one 
generation 
   to the next
  How ideas, traditions, physical 
 traits, and even disease become 
   the legacies we inherit.
spring 2015 
volume 49, number 2
yalemedicine.yale.edu2
letters
  “Almost every disease  
is influenced in some  
 manner by inheritance”
HOW D O OU R I N H E R I T E D T R A I T S, both 
genetic and environmental, determine who we 
are? We asked Yale faculty and students to reflect 
on this question in many ways for this issue of 
Yale Medicine. Dean Robert J. Alpern, M.D.,  
discussed what he has inherited from those who 
served as dean before him, and the importance 
of evolution and heredity to science. 
This issue of Yale Medicine explores the concept of inheri-
tance from many angles. What makes this subject so rich?  
Almost every disease is influenced in some man-
ner by inheritance, including not only genetics and 
epigenetics, but that which we “inherit” from the 
environment our parents establish for us. While many 
diseases involve random environmental factors, our 
response to those elements is determined by our 
genetic background.
As a scientist, what interests you most about inheritance?  
Evolution has a profound effect on everything we are, 
including the diseases that affect us and our response 
to those diseases. When humans were content to live 
until their children became independent, evolution 
was our friend. Now we live long past the age required 
for survival of our species, and we are on our own with 
no support from evolution.
You are the 16th dean of the School of Medicine. What have 
you inherited from your predecessors? I have inherited 
many great things from previous deans, among them 
the Yale system of medical education, and a preemi-
nent medical school.
What do you imagine our legacy—that of YSM of the early 
21st century—will be? I hope that our legacy will be that 
we have advanced excellence in education and research, 




















I N M A RC H 20 01, Esther K. Choo, M.D. ’01, then a medical 
student, was bouncing around in a jeep on bumpy desert 
roads in Gujarat, India, feeling sick from the heat and the 
antiretroviral medications she was taking. At her side 
was fellow medical student Vivek H. Murthy, M.D. ’03, 
M.B.A. ’03. They were part of a team from Yale that was 
providing relief after an earthquake. On this mission they 
also addressed medical needs unrelated to the immedi-
ate crisis. While drawing blood samples at a screening 
for diabetes and cardiac disease, Choo pricked her finger 
with a used needle. She and Murthy were scouring the 
countryside for the woman whose blood she had been 
exposed to, so they could test her for HIV. They found the 
woman, and she tested negative. “Vivek volunteered to go 
with me to hold my hand and keep me from freaking out,” 
Choo said. “He is just that kind of person.”
  Alum’s appointment  




Vivek Murthy became the 
fi st graduate of the School 
of Medicine and the first 
American of Asian descent 
to be confirmed as the  
U.S. Surgeon General.  
Vice President Joe Biden 
swore him in during a 
ceremony on April 22.
While in Gujarat, said Choo, 
now an emergency physician at 
Brown University, one of their 
faculty preceptors told the stu-
dents that they were all bright 
but that Murthy would make his 
mark in a very big way. “None of 
us took offense, because it was 
so obvious,” Choo said. “He was 
the moral center of the group. 
He was unflappable and calm, 
no matter what was going on.”
In January the U.S. Senate 
confirmed Murthy’s appoint-
ment as the nation’s 19th sur-
geon general. His nomination 
by President Barack Obama 
had been on hold for more than 
a year due to opposition from 
Republicans and the National 
Rifle Association. His offense? 
A 2012 tweet on gun violence: 
“Tired of politicians playing poli-
tics w/guns, putting lives at risk 
b/c they’re scared of NRA. Guns 
are a health care issue.” He was 
also criticized for his youth and 
relative inexperience—he is 38. 
Yet support came from more than 
100 national health organizations, 
including the American College 
of Physicians, the American 
Public Health Association, the 
American Cancer Society, and 
the Association of American 
Medical Colleges, as well as from 
two former Surgeons General.
Anyone at the med school 
between the fall of 1998, when 
Murthy matriculated, and 
2003, when he graduated, prob-
ably has a story about him. As 
one student of that time put 
it, “Everyone knows Vivek.” He 
arrived at Yale with a record of 
accomplishment dating back to 
his high school days in Florida, 
when he got his classmates to 
mentor middle school students. 
As a Harvard undergrad, he 
launched a peer education pro-
gram that trained American 
college students to teach stu-
dents in India about HIV/AIDS. 
He also started a community 
health partnership in rural India 
that trained young women to 
be health educators and basic 
health care providers. During 
his first year as a med student, 
he was profiled in The Chronicle 
of Philanthropy for his efforts.
When he spoke, classmates 
said, others paid attention. “He 
would often listen quietly to 
a discussion of a controversial 
topic,” former class president 
Andrew D. Norden, M.D. ’02, 
M.P.H., now a neurologist in 
Boston, wrote in an email. “He 
would wait until the opposing 
viewpoints were on the table 
and finally make a critical com-
ment that recognized an under-
standing of each position, and 
suggest a thoughtful path to 
resolution. He frequently got the 
last word in because once he had 
spoken, everyone could be seen 
nodding in agreement.”
Auguste H. Fortin VI, M.D., 
M.P.H., associate professor of 
medicine, recalled Murthy 



























Watch the first TV 
interview with the new 
surgeon general on 
cbsnews.com. Vivek 
Murthy is the first  
Yale alumnus to serve  
in the post and one  
of the youngest in  
recent memory.
And for more on  
Murthy’s swearing- 




Defending the “good” 
bacteria
When faced with dangerous 
bacteria like Salmonella, the gut 
releases inflammatory molecules 
to destroy the invaders. That 
immune response is so nonspe-
cific that in theory at least, it 
should kill indiscriminately. Yet 
the many healthful and even 
beneficial bacteria that reside in 
the gut seem unaffected by the 
friendly fire. So-called com-
mensal strains persist for years 
through one inflammatory event 
after another.
A group of researchers led 
by Andrew Goodman, Ph.D., 
assistant professor of microbial 
pathogenesis and a member of 
the Microbial Sciences Institute 
at West Campus, recently fig-
ured out why: many of the most 
prominent and stable commen-
sals wield a protein that fends 
off the antimicrobial peptides 
(AMPs) that the host uses to 
attack the invaders. The team 
reported in Science in January 
that the protein LpxF serves a 
little like an umbrella, allowing 
bacteria to readily shed AMPs 
at concentrations thousands of 
times higher than those that 
kill pathogens.
The discovery, said Goodman, 
opens the door for researchers to 
learn “not only how the host tol-
erates the microbiome—which is 
well studied—but how the micro-
biome tolerates the host.”
LpxF works by removing a 
negatively charged phosphate 
group from the bacterial sur-
face. That keeps the positively 
University of California, San 
Francisco (UCSF), where he’d sat 
in on “The Healer’s Art,” a class 
that explores the human dimen-
sions of medicine, taught by 
Rachel Naomi Remen, M.D.
“He came back very excited 
and enthusiastic,” Fortin said. 
“He said we have to do this at 
Yale. He recognized that there 
was a need for students to talk 
about meaning in medicine.”
Murthy worked with Fortin 
and Margaret J. Bia, M.D., 
FW ’78, professor of medicine, 
to establish The Healer’s Art, a 
small-group elective now in 
its 15th year. Over four weeks, 
students discuss such topics 
as what it means to be a healer, 
what it’s like to lose a patient, 
and how to avoid burnout. Yale 
was the first medical school 
after UCSF to offer the course, 
and now more than 70 medical 
schools have followed suit. “I 
think we have Vivek to thank 
for that,” Fortin said.
After graduating from Yale, 
Murthy founded TrialNetworks, 
social networking platforms 
for clinical trials that enhance 
communication, collaboration, 
and overall efficiency. During 
the 2008 presidential campaign 
Murthy and colleagues founded 
Doctors for Obama. After the 
election, the group became 
Doctors for America, a grass-
roots organization of doctors 
and medical students working to 
improve access to health care. In 
2011, President Obama appointed 
Murthy to the national Advisory 
Group on Prevention, Health 
Promotion, and Integrative and 
Public Health. The following  
year Murthy served as co-chair 
of the health care advisory  
committee for Obama’s re- 
election campaign.
During the more than year- 
long wait for a vote on his  
nomination, Murthy remained 
optimistic. And when he re-
turned to Yale as the medi-
cal school’s Commencement 
speaker last year, students wore 
decals on their gowns that read 
“Yale Stands with Vivek.”
“Those of us closest to Vivek 
during this time maintained our 
optimism,” said one of his men-
tors, Howard P. Forman, M.D., 
professor of diagnostic radiology, 
of economics, of management, 
and of public health (health 
policy), and director of the 
M.D./M.B.A. Program. “We were 
very certain there was a win-
dow of opportunity, and that 
his many supporters, including 
those in the White House, would 
use that to the best advantage. 
Despite the rhetoric before the 
confirmation, I think that he is 
a thoughtful, nonpartisan, very 
deliberate physician who sees 
the role of the Surgeon General 
as an amazing opportunity to  
be the nation’s leading spokes-
person on health and public 
health issues.”
“Vivek does everything so 
selflessly and is one of the bright-
est, off-the-charts-smartest 
people that I know,” said Choo. 






A caring surgeon,  
struck down in an act  
of senseless rage
Michael J. Davidson, M.D. ’96, 
was a heart surgeon, one of a 
fraternity well-known for its 
bravado, but family, friends, and 
colleagues remember him as 
one of the gentlest souls ever to 
wield a scalpel. 
He practiced in an area of 
medicine where a clear divide 
separates cardiac surgeons from 
cardiologists, but he trained 
as both. He spent unhurried 
hours with patients and their 
families, answering their ques-
tions, calming their fears, and 
earning their gratitude—until, 
one morning in January, the son 
of a patient shot Davidson out-
side an exam room at Brigham 
and Women’s Hospital (BWH) 
in Boston. Davidson died hours 
later, despite the best efforts of 
his colleagues.
His assailant, a 55-year-
old man from the Boston area, 
was subsequently found dead, 
apparently from a self-inflicted 
gunshot wound. Police said the 
shooter blamed Davidson for his 
mother’s death in November.
“Surgeons are not known 
for their bedside manner, but 
Michael had it in spades,” said 
Terri Halperin, M.D., Davidson’s 
wife. “That is why the fact 
that a patient’s family mem-
ber would take Michael away 
from us makes it all the more 
devastating.”
At his funeral in Wellesley, 
Mass., Davidson was recalled as 
a problem solver who could take 
there are dedicated mecha-
nisms that we can identify and 
potentially target.”
LpxF is likely to be one of 
many resiliency factors wait-
ing to be discovered in the gut, 
some of which may point to 
new drugs. This line of study is 
especially important because 
faulty or damaged resiliency 
systems might explain certain 
forms of disease. Studies of the 
gut microbiome have typically 
focused on the bacterial com-
munities of healthy people. But 
understanding how these com-
munities behave in sick people is 
crucially important, too. That’s 
Goodman’s next goal.
—Jenny Blair
charged AMPs—the gut’s 
defenders—from binding to bac-
teria and destroying them.
The LpxF discovery and 
its satisfying simplicity may 
mean that the field—which has 
focused mostly on describing its 
species diversity—is now poised 
to move into an exploration of 
how the ecosystem functions. 
Understanding that ecosystem 
is a sine qua non for pursuing 
potential therapeutic targets.
Goodman, who is trained 
in both microbial genetics and 
ecology, had previously assumed 
that the host-pathogen com-
mensal relationship would be 
byzantine and difficult to study. 
Now he is optimistic.
“It’s a glimmer of hope that 
it’s not going to be so irreduc-
ibly complex that we won’t be 
able to make any headway,” 




















apart and fix a refrigerator or 
install a hardwood floor. He did 
his own electrical work. Before 
coming to Yale, he earned his 
bachelor’s degree at Princeton, 
where he was a competitive 
fencer and president of the soar-
ing club. In college he taught 
himself to play the guitar and 
played in a rock band. He decided 
to run the Boston Marathon on 
his 40th birthday and finished 
with a respectable time.
“We would have everything 
from live lobster races on the 
floor of our apartment, to the 
annual tradition of our Passover 
turkey, to 10-course, free-form 
Asian explorations with five 
woks going,” recalled Joshua M. 
Rosenow, M.D. ’96, his medical 
school roommate for three years. 
In interviews, others who 
knew him struggled to under-
stand how Davidson had become 
the object of rage. “None of it 
makes sense,” said Jamie M. 
McCabe, M.D. ’04, who trained 
under Davidson at BWH for 
two years. “He was a calm and 
thoughtful guy, an extremely 
hard worker, and very dedicated. 
He was just a genuinely sweet 
person.” Davidson’s thesis advi-
sor, Robert J. Touloukian, M.D., 
remembers him as “very soft-
spoken, intelligent, inquisitive.”
“There are people in surgery 
who are fundamentally aggres-
sive. Mike was fundamentally 
a very gentle and caring per-
son,” said Samantha Hendren, 
M.D. ’96, M.P.H., a colorectal 
surgeon at the University of 
Michigan. “That makes it all  
the more unjust that his life 
ended violently.”
Davidson was director of 
endovascular cardiac surgery at 
BWH and a member of the fac-
ulty at Harvard Medical School. 
During his residency, he moved 
from Duke to Boston to be with 
Halperin, and he completed fel-
lowships in endovascular sur-
gery and cardiac catheterization 
and in cardiac surgery.
Frederick C. Welt, M.D. ’92, 
met Davidson at BWH. With 
their colleague Andrew C. 
Eisenhauer, M.D., they led the 
team that implemented trans-
catheter valve replacement at 
BWH. The minimally invasive 
technique had been pioneered 
in France in 2002 and, accord-
ing to Welt, “involved coopera-
tion between surgeons and 
cardiologists—not always an 
easy thing to do.”
“Mike was incredibly talented. 
He was already obviously a well-
trained surgeon, yet he took a 
year out of his life to cross-train 
in the world of interventional 
cardiology,” Welt, now at the 
University of Utah, wrote in 
an email. “It was an effort that 
took time away from the OR, 
and he paid a financial price for 
that in terms of the operative 
time that he gave up. But he was 
completely committed, and … he 
developed into somebody who 
was really as good with those 
skills as anyone at the table.”
Davidson recognized that 
the dividing lines between 
disciplines were “weird and 
arbitrary,” added McCabe, his 
former trainee, “and that the 
best way forward was building 
those really tight bonds between 
interventional cardiology and 
cardiothoracic surgery to pro-
vide a kind of whole new spec-
trum of care.”
According to Michael 
J. Zinner, M.D., chair of the 
Department of Surgery at BWH, 
Davidson “was one of only two 
or three cardiac-trained sur-
geons in the country who were 
doing this kind of work and 
would go on … to make incred-
ible innovations in this area.”
Davidson’s former chief, 
Ralph M. Bolman III, M.D., 
agreed. “Mike had a vision for 
a new heart doctor, one who is 
really going to be, and is, the 
doctor of the future,” Bolman 
said. “He was one of the very 
first to act on this vision.”
—Michael Fitzsousa
online exclusives
Classmates Michael Davidson, right, and 
Josuha Rosenow, together on Match Day in 
March 1996. Rosenow recalled the moment 
upon seeing the photo in February 2015 for 
the first time: “Michael had just received his 
match results, and I was holding up one finger 
because he got his first choice.”
How two second-years 
launched a course in 
health justice
Yale med students join  
in national protest
Storytelling at the heart 
of the medical enterprise
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 




 THE “NOISE” 
IN HUMAN CELLS
A Yale-led team of scientists has 
developed a method for mapping cel-
lular “noise,” variations in how human 
cells react to chemical signals. Their 
findings, published in Proceedings 
of the National Academy of Sciences, 
could help tailor drug delivery and 
advance semiconductor chip design. 
The method, devised by systems biolo-
gist and biomedical engineer Andre 
Levchenko, Eng.Sc.D., is based on 
each cell’s unique reactions to chemi-
cal signals—some cells react strongly, 
while other cells may not react at all. 
“Knowing how variable the activity is 
allows us to better target the spec-
tra of activities in those networks,” 
said Levchenko, the John C. Malone 
Professor of Biomedical Engineering 
and inaugural director of the Systems 
Biology Institute at West Campus.
Yale surgeons and biomedical engi-
neers are working with a biology 
company to develop 3-D printed 
tissues for transplant research. With 
demand for transplanted organs 
and tissues increasing and supplies 
shrinking, 3-D organs would shorten 
the amount of time patients would 
have to wait. Since the transplanted 
cells would come from the patient’s 
 SURGEONS AND ENGINEERS  
JOIN FORCES ON 3-D ORGANS
 PSYCHOLOGIST  
DECODES “TEARS OF JOY”
own body, the technology would 
eliminate the need for immunosup-
pressive drugs. “This field may provide 
a unique and new opportunity where 
we can print 3-D organs that can 
supplement or replace the shortage 
of organs out there worldwide,” said 
John P. Geibel, D.Sc., M.D., vice chair 
and director of surgical research and 
professor of surgery (gastrointestinal) 
and of cellular and molecular physi-
ology at the School of Medicine. In 
the first phase of the collaboration 
with Organovo Holdings Inc., Yale 
researchers would develop 3-D arter-
ies and veins that would replace 
plastic stents as connective tissue 
in transplants. The second phase of 
the project would involve printing an 
entire organ—the small intestine.
 A Yale team led by Ifat  
Levy, Ph.D., assistant professor in  
comparative medicine and neuro-
biology, reported in the Journal of 
Neuroscience in September that 
people who have larger volume in a 
particular part of the parietal cortex 
are willing to take more risks than 
those with less volume. “Based on  
our findings, we could, in principle, 
use millions of existing medical  
brain scans to assess risk attitudes  
in populations,” said Levy. “It could 
also help us explain diff rences  
in risk attitudes based in part on 
structural brain differences.”
Why do people emit a nervous laugh 
in uncomfortable situations? And why 
are parents who cry at their child’s 
graduation also more likely to pinch 
a cute baby’s cheeks? Yale psycholo-
gist Oriana R. Aragón, Ph.D., ’14, now 
understands why people cry when 
they are happy. “People may be restor-
ing emotional equilibrium with these 
expressions,” said Aragon, lead author 
of work published in Psychological 
Science. “They seem to take place 
when people are overwhelmed with 
strong positive emotions, and people 
who do this seem to recover better 
from those strong emotions.”
  THE BIGGER YOUR  
PARIETAL CORTEX,  
 THE BIGGER THE  









































a collection of recent  
scientific findings
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IN THE L ATE 1970s, an archaeologist exploring the Colombian Andes for 
tombs and relics of past civilizations met an elderly farmer who told him 
of a field where, as a child, he had been forbidden to play. Thefield was 
dangerous, his mother told him, because of the two-headed monster that 
lived there. Thearchaeologist and his team excavated the site—buried in 
the field, they found the full-size statue of a man with two heads.
Who made the statue and how it came to be buried there remained 
mysteries. Yet somehow, as in a game of Telephone, knowledge of the 
statue had passed down through the generations. With each telling, the 
story changed. DNA similarly passes from generation to generation, but it 
doesn’t always come out right. Ideas move through time, and they change 
with the times. We inherit many things from our ancestors, be they blue 
eyes and brown hair, notions of right and wrong, or just habits and ways 
of being. In this issue of Yale Medicine, we look at the ways in which 
these inheritances emerge intact—or sometimes not.
This issue’s feature articles explore what DNA reveals about human his-
tory, how med school traditions endure or fall by the wayside, and how 
one family copes with an inherited disease.
yalemedicine.yale.edu10
 From one  
generation to the next
How ideas, traditions, physical traits, and even  
disease become the legacies we inherit.
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 Six degrees  
of Paul Beeson
T H E I RON T E R N S, as they were known, began their internships in medicine 
under Paul Beeson, M.D. (fifth from left, front row) in the 1960s. Jack Levin, 
their chief resident, coined the name at a softball game marking the end 
of their internship year. The name was an abbreviation of intern and their 
moniker of “iron men” for their stamina on the wards. Of the 14 physicians in 
this group, nine went on to become full professors; four held endowed chairs; 
five became department chairs; one became a medical school dean; and two 
became division chiefs. Collectively, they published more than a thousand 
articles. The legacy of Paul Beeson, dubbed the “Beeson mystique,” has been 
handed down through them to later generations of physicians. In June 1965, 
the Iron Terns posed on the steps of the Sterling Hall of Medicine with Beeson 



















M.D., HS ’69, FW 
’73, was in private 
practice in Maine.
1
Michael Viola, M.D., 
HS ’66, delivers 
health care in 
the developing 
world as the chief 
medical officer 
of Medicine for 
Peace, which 
he and his wife 
founded along 
with the MFP 
Center for Torture 
Victims in Wash-
ington, D.C. In his 
earlier career he 
was a professor of 
medicine at the 
University of Con-




M.D. ’64, HS ’70, 
was dean of the 
medical school 
at Northwestern 











M.D., HS ’65, was 
in private practice 
in psychiatry in 
New York City and 
Laguna Beach, 
Calif. He was also 
a member of the 
part-time facul-
ties of the schools 
of medicine of Co-
lumbia University 
and the Univer-
sity of California, 
Irvine.
6
Dave Dear, M.D., 
HS ’66, a cardiolo-
gist, lowered the 
mortality rate 
in heart surgery 
from 50 percent 
to 1 percent in  
just one year  
in a hospital in 
Mississippi.
2
James J. Fischer, 
M.D., Ph.D., HS 
’65, was chair 
of therapeutic 
radiology at Yale 
for 30 years, and 
played a major 
role in improving 
radiation therapy.
3
Larry Knight, M.D., 
HS ’67, FW ’68, 
was both chief  
of staff nd chair  
at the Elkhart 
Clinic in Indiana, 
an early multi- 
specialty clinic.
4
Paul Beeson, M.D., chaired internal medicine 
from 1952 to 1965 and taught the importance of 
treating patients as human beings. He mentored 
scores of young doctors who went on to make 
their mark in medicine.
yalemedicine.yale.edu14
Jack Levin, M.D. 
’57, HS ’65, though 
not an iron tern, 
served as their 
chief resident. He 
was a professor 
of medicine at 
Johns Hopkins and 
professor of labo-
ratory medicine 
and medicine at 
the University of 
California, San 
Francisco. At the 
Marine Biologi-
cal Laboratory in 
Woods Hole, Mass., 
with his colleague 
Frederik Bang, 
M.D., he devel-
oped the Limulus 
amebocyte lysate 
test, which is used 
to detect bacte-






Richard Lee, M.D. 
’64, HS ’70, FW ’71, 





tive medicine.  
He wrote 44 es-
says for the 
American Journal 
of Medicine; 
81 essays and 
commentaries; 
and a book on his 
medical travels.
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John Burke, M.D., 
HS ’67, was one 






He trained 70 fel-
lows in infectious 
diseases at the 
University of Utah.
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John N. Forrest Jr., 
M.D., HS ’70, FW 
’71, has directed 
student research 
at Yale for 29 
years, and has 





9 Peter Gross, M.D., 
HS ’66, FW ’71, 
spent much of 




ment, and was 
chair of medicine 
at Hackensack 
University Hospi-
tal in New Jersey.
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Harold Federman, 
 M.D., HS ’65, per-
sonally delivered 
hospice and 
palliative care to 
hundreds of pa-
tients while estab-




Hugh Tilson, M.D., 










policy research at 
GlaxoWellcome. 
Most recently, 
he has served 
as a county 
health officer in 
Bath, Maine, and 
adjunct professor 
at the UNC School 




man, M.D., HS ’69, 
moved into the 
business world 
after a career at 
the University of 
Connecticut. He 
became the chair, 
CEO, president, or 
managing director 





























 Written  
in blood
Ken and Judy Kidd’s bank of  
2,600 cell lines contains the 
secrets of our evolution and  
perhaps our future health— 
why would they destroy it?
By Kate Wheeling | Robert A. Lisak Photos
In 1959, in a burgeoning riverside market town in what 
was then the Belgian Congo, a Bantu man fell ill.
An unknown virus was replicating furiously in the 
white blood cells circulating in his veins. A sample 
of his blood, taken for a study of the genetic diseases 
of red blood cells, was frozen and forgotten for nearly 
three decades. It contained traces of the mysterious 
virus that would take some 20 million lives worldwide 
by the year 2000: the human immunodeficiency virus 
(HIV), a retrovirus that thrives within the very cells 
meant to fight off invaders.
Blood is an ephemeral substance. Red blood cells, 
which make up nearly half of the blood’s volume, have 
a life span of just 120 days, give or take a week. Four 
months from now, every one of the 25 trillion or so bi-
concave blood cells sailing through the body’s veins 
and arteries at this moment will have been consumed 
by macrophages and replaced by brand-new oxygen-
toting cells. Outside the body, blood cells break down 
in 24 hours or less.
Frozen blood, on the other hand, is a liminal sub-
stance—neither alive nor dead. The Bantu man’s frozen 
blood became a snapshot of the past, and as medi-
cal technology and tests advanced, a resource for the 
future. Eventually, the Bantu man’s blood would help 
scientists trace the origins of one of humanity’s deadli-
est epidemics.
Not only can frozen blood be used to track the 
spread and evolution of the diseases that plague 
humans, but it can also transcend disciplines, provid-
ing valuable insights to geneticists, anthropologists, 
and immunologists alike. Within those blood cells are 
traces of humanity’s evolutionary history.
For more than four decades, blood has been the main 
focus of the work of Kenneth K. Kidd, Ph.D. A professor 
of genetics, of ecology and evolutionary biology, and of 
psychiatry at Yale, Kidd got his start in genetics at the 
University of Wisconsin, where he studied blood group 
typing to identify and register purebred cows.
In the 1980s, when population geneticists acquired 
the tools to look directly at DNA, Kidd and his wife, 
Judith R. Kidd, Ph.D. ’93, switched to human subjects. 
“We gradually moved more and more into population 
studies, just because they’re fascinating,” said Ken. The 
Kidds became interested in the genetic variations that 
occur between geographically distinct populations.
“There is just a terrific amount you can learn from 
the study of human populations,” said Judy, a retired 
research scientist in the Department of Genetics 
who earned her Ph.D. in anthropology. “When Ken 
was studying cattle genetics as a graduate student, I 
thought, ‘Oh, that’s interesting.’ But once he moved to 
humans, I thought, ‘Oh, that’s interesting!’ ”
Their work on genetic variation has helped to piece 
together the human genetic map. The Kidds have 
scoured the genome for genes involved in complex 
neuropsychiatric disorders, narrowing down genes 
that play a role in Tourette syndrome, schizophrenia, 
and alcoholism. They’ve also used DNA polymorphisms 
to trace human origins. Their research has shown 
that sub-Saharan African populations tend to have 
more variation in certain genes than other popula-
tions throughout the world, which could mean that 
the genes have had more time to accumulate mutations 
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Kenneth and Judith Kidd have 
collected blood samples from 
around the world. Those samples 




and diversify in those African groups. This work bol-
sters the theory that modern humans spilled out of 
Africa to populate the rest of the world.
The Kidds share all the data on genetic variation they 
collect in a publicly accessible bioinformatics database 
that they affectionately call ALFRED, short for the Allele 
Frequency Database. But the physical cell lines them-
selves are locked inside steel-colored freezers in their 
New Haven lab. As the Kidds wind down their careers, 
what will happen to their collection is an open question.
a “co l d c h a in” t o mo v e bl o od
Cold storage is not new; insulated iceboxes have been 
around for at least 200 years. Your grandmother prob-
ably had a mechanical refrigerator to keep her per-
ishables cool before one was ever used to chill blood. 
Radin, an assistant professor in the history of medicine 
whose work examines the ways in which technologies of 
cold storage have transformed the practice of biomedi-
cine and public health. This chain was not without kinks. 
In 1968, a World Health Organization (WHO) report 
advised researchers to scratch serial numbers directly 
onto the glass vials after several shipments of specimens 
were unidentifiable upon arrival at labs—presumably, the 
labels had washed off in melted ice.
The WHO, famous for its work on infectious dis-
eases, was quick to recognize the potential benefits of 
cold storage. The agency saw the collection of serum, 
the liquid component of blood, as a way to expand  
the study of current diseases in remote parts of the 
globe and to prepare for the diseases of the future.  
As new diseases—and tests for their detection—
emerged, researchers could thaw frozen serum sam-
ples and study them in light of such medical advances.
The agency established four serum banks, reposi-
tories of frozen samples, to serve as a biomedical 
resource. The only one in the Western Hemisphere was 
  Joanna Radin // 
 “Choices made in the past have consequences  
for the present, and what might have seemed ethical  
   in one place and time will change. ’’
Mechanical refrigeration replaced consumer iceboxes in 
the 1930s—before that, commercial refrigerators were 
as likely to catch fire, explode, or leak toxic gas as they 
were to keep things cold—but the technology didn’t take 
off in the scientific world until World War II.
Soldiers scattered across the globe in need of blood 
transfusions led to the creation of a “cold chain” for blood 
transportation. This chain moved stateside blood dona-
tions to soldiers on the front lines, requiring not just 
fridges and freezers at collection sites, but also something 
to keep blood cold in transit: dry ice and liquid nitrogen.
Yale medical historian Joanna Radin, Ph.D., found that 
by the 1960s, scientists had reversed the flow of these 
cold channels, using the infrastructure devised during 
wartime to learn more about human biology. Blood col-
lected from remote populations around the world could 
be shipped to high-tech laboratories for analysis, said 
opened at Yale in 1960. The WHO chose John Rodman 
Paul, M.D., to direct it.
Paul, chair of the Section of Epidemiology and 
Preventive Medicine at Yale, had used blood samples 
to study the spread of diseases like polio and was an 
early proponent of freezing biological specimens. In 
the 1940s, while investigating antibody patterns in 
Eskimos in northern Alaska, he froze serum samples 
so that he could reanalyze each one as tests for newly 
discovered antigens became available. After more than 
a decade of studying the same samples, Paul still found 
the frozen serum to be a fruitful source for epidemio-
logical research. “Indeed,” he wrote in 1961, “the epi-
demiologic story which this work has gradually been 
unfolding is not yet finished.”
The reference serum bank at Yale, whose rise was 
the subject of Radin’s research, quickly became a hub 
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for the advancement of epidemiological research. In 
1966, Alfred S. Evans, M.D., M.P.H., professor of epi-
demiology, took over as the second director of the 
bank. In that year alone, more than 21,000 serum 
samples were handed out to scientists who wished to 
study them. Before the decade was out, the Yale col-
lection had grown to over 25,000 individual samples. 
Yale could no longer house the substantial collection, 
and the bank moved to a building owned by the New 
Haven Cold Storage Co. By the 1990s, when the collec-
tion moved from Yale to the National Cancer Institute 
in Bethesda, it contained over 50,000 unique serum 
samples—and untold insights into the infectious and 
chronic diseases of the past and present.
A prescient WHO report released in 1959—the same 
year the Bantu man’s blood was collected and frozen—
stated: “If samples of the sera collected in these surveys 
are stored in such a way as to preserve antibodies, it 
will be possible to examine them in the future and so to 
determine the past history of infections as yet unknown 
and to follow more clearly the changing pattern of com-
municable disease all over the world.”
Two decades later, HIV emerged as a devastating 
pathogen. In the early 1980s, young, otherwise healthy 
people the world over began to waste away, dying of 
infections that usually felled only the old: tuberculo-
sis, bacterial pneumonia, cryptococcosis, and herpes 
among them. Eventually, researchers discovered that 
HIV was at the heart of this immune system failure. 
Scientists sought the origins of this viral invader, hop-
ing that understanding where the virus came from 
might provide clues for a cure or, at the very least, 
a way to contain it. In 1998, researchers from The 
Rockefeller University tracked it down to a freezer at 
Emory University in Atlanta. The freezer held more 
than 1,000 blood samples collected in the Congo in 
1959 for a study of an inherited blood disorder com-
mon among some Africans. Once HIV was isolated as 
the cause of AIDS, an Emory scientist told a colleague 
about those samples. Only one sample, belonging to a 
Bantu man from a riverside market village, tested posi-
tive for HIV antibodies, making it the oldest biological 
trace of the disease ever documented.
With this and other preserved HIV-positive tis-
sues, researchers used the known mutation rate of the 
virus to approximate when the epidemic began. By 
2008, scientists had estimated that HIV crossed over to 
humans from chimpanzees somewhere in southeastern 
Cameroon a century earlier, about 1908. And a greater 
understanding of both the origin of the virus and its 
mechanisms of action has contributed significantly to 
medical advances against the disease.
a qu est i o n of  o w n er sh ip
The WHO didn’t advocate preserving biological samples 
just because they might come in handy in the future, 
Radin has shown; the agency was equally interested in 
preserving the past. Frozen blood samples could also 
serve as permanent genetic snapshots of indigenous 
populations that began disappearing almost as soon as 
In the early days of genetics research, it took a lot of DNA to 
look at one polymorphism, so the Kidds transformed their 
blood samples from a hodgepodge of cells and proteins 
into immortal cell lines from which they could extract DNA 
whenever they ran low. To create cell lines, the pair infect 
blood cells with Epstein-Barr virus, a common human 
herpesvirus. Once inside the cell, the viral genome makes 
its way into the cell’s nucleus and begins creating copies of 
itself. As the virus replicates, it produces proteins that pro-
voke the human cells to proliferate indefinitely. The Kidds 
freeze each cell line until they need the genes for research. 
They use chemicals to break open the cell walls, spilling out 
the cellular structures and DNA alike, then use a centrifuge 
to separate the genetic material from the debris. In addi-
tion to being a source of DNA, the cells are also potentially 
useful as living cells for a variety of research questions. To 
date, the Kidds have collected samples from 55 populations 
throughout the world and created nearly 2,600 cell lines.
 Cell lines offer  
a look into the past
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they were discovered, and help to unravel humanity’s 
evolutionary history.
By the mid-20th century, globalization was heating 
up. The WHO envisioned a future of both environmen-
tal and cultural upheaval, in which lands and peoples 
would be overwhelmed by the spread of Western 
influences. According to Radin, the WHO considered 
so-called “primitive” island populations to be unique 
laboratories “in which nature had run experiments on 
humans for thousands of years.”
These populations provided unique windows into 
our evolutionary past, and according to the WHO, they 
were also vanishing. Scientists scrambled to collect 
blood samples from remote and endangered peoples to 
preserve their genetic fingerprints. Yale would become 
the home of a second massive collection, different from 
Paul’s bank of serum samples because it contained cell 
lines. Today, one of the largest collections of anthro-
pologically relevant cell lines resides in the Kidds’ lab, 
according to Radin.
“Some of these samples are never going to be collect-
able again,” said Ken Kidd. Their collection contains sam-
ples from diverse populations, from the Atayal tribe in 
Taiwan to the Zaramo people of Tanzania. But these iso-
lated populations are not necessarily dying off, as WHO 
officials imagined they might, but rather integrating into 
societies that have grown up around their territories. 
According to Ken Kidd, whether indigenous groups are 
dying or assimilating, such change “obliterates a window 
into the past.”
Still, many of the cultures that the WHO expected to 
disappear are alive and well. “Cold War-era scientists’ 
vision of the future did not include a world in which the 
barriers to collecting such blood would come from these 
peoples themselves,” wrote Radin.
There are many reasons why a group would object to 
how their blood samples might be used. The Havasupai, 
a community that lives deep within carved cliffs of the 
Grand Canyon, is a prime example. In the 1960s, rates of 
diabetes among tribe members mysteriously skyrocketed. 
Thirty years later, a geneticist at Arizona State University 
in Phoenix parsed the tribe’s DNA for the cause. Roughly 
100 tribe members volunteered blood samples, but when 
they later learned that those samples had been used for 
other studies, including one that proposed a theory of the 
tribe’s origins that contradicted the group’s own creation 
myth, they balked. After a lengthy legal battle, the uni-
versity paid reparations and returned the blood samples.
Ten years after their cells had been immortalized in 
a cell line, another group of Native Americans, whom 
the Kidds prefer not to name for legal reasons, asked that 
their cells be returned to them even though they had 
originally given full informed consent. But because the 
process of transforming a cell into a cell line involves 
infecting it with a virus, those cells are designated a bio-
hazard—the Kidds couldn’t ship them to anyone without 
a functioning lab and a qualified technician. The group 
settled for having the cell lines and DNA destroyed. “The 
head of the Human Investigation Committee here at Yale 
watched us thaw out and destroy all the frozen cell lines,” 
said Ken. The DNA that had been isolated from those cells 
was “cooked” in an autoclave.
“That was painful,” Ken said of the ordeal. “Oh, it was 
heartbreaking,” added Judy. Today, the Kidds’ entire col-
lection faces an uncertain future.
Judy retired in 2011, and Ken is likely to retire by 2016. 
It’s unclear what will become of the cell lines they’ve 
spent their careers studying. “It’s a matter of interest and 
responsibility and money,” said Judy. “There are lots of 
things we could do that wouldn’t make me feel as good 
as keeping those cell lines right here at Yale.” Ideally, the 
collection will remain at Yale, perhaps in the Peabody 
Museum as a frozen gallery of sorts, where a technician 
can watch over the cells, monitor liquid nitrogen levels, 
and send cell lines to qualified researchers. The scientist 
or organization, at Yale or elsewhere, who takes respon-
sibility for the cells will be responsible for ensuring both 
the immortality of the cells and the immortality of the 
promises that were made to donors when they gave their 
blood to research. If both needs aren’t met, all 2,600 lines 
will have to be destroyed.
If the cells remain in the freezers, they could yield 
untold knowledge for future generations of researchers. 
The issue remains, however—the needs of science may 
conflict with the social and ethical questions raised by 
the maintenance of cold blood. “They are not always 
likely to be in alignment,” Radin said. “Choices made 
in the past have consequences for the present, and 
what might have seemed ethical in one place and time 
will change.” /yale medicine
Kate Wheeling was Yale Medicine’s 2014 writing intern.
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 Was pharaoh’s  
odd appearance genetic?
A K H E NAT E N, T H E E GY P T I A N RU L E R who was husband to 
Nefertiti and father to Tutankhamen, is best known for two 
things: he was the first historical figure to embrace mono- 
theism, and he was “one funny-looking pharaoh,” according  
to Irwin M. Braverman, M.D. ’55, HS ’56, a Yale dermatologist  
with overlapping passions for art and medicine.
Scholars have attributed this odd 
appearance—androgynous, with wide 
hips, an elongated head, almond eyes, 
square jaw, and womanly breasts—to 
various causes. Early representations 
of the pharaoh depict a normal 
head and body, but after Akhenaten 
embraced the Sun-disk god, Aten, as 
the one and only deity, his gender in 
sculptures and carvings became more 
ambiguous. His changing appear-
ance has led to speculation that the 
depictions were metaphorical, meant 
perhaps to portray Akhenaten as the 
father and mother of all humankind.
Opposing explanations sug-
gest that the changing images were 
realistic and reflect a genetic disor-
der. Braverman is firmly in this sec-
ond camp. “This is not just artistic 
license,” says Braverman, professor 
emeritus of and senior research sci-
entist in dermatology and co-author 
of a 2009 paper in the Annals of 
Internal Medicine that examined 
the issue. With colleagues from 
Maryland and Pennsylvania, he 
proposed that two familial disor-
ders—aromatase excess syndrome 
and sagittal craniosynostosis  
syndrome—were the most likely 
candidates. A third possibility is 
a mutation in the gene for a class 
of enzymes that was responsible 
for both the cranial and endo-
crine abnormalities of members of 
Egypt’s 18th dynasty. Braverman 
would like to settle the question 
through DNA analysis of mummi-
fied remains, but attempts to obtain 
samples have been unsuccessful.
If Akhenaten passed down gene 
mutations that conferred his strange 
physical characteristics on his prog-
eny, he did not pass on his most 
notable quality, belief in only one 
god. Despite the pharaoh’s single-
minded concept, the Sun-disk did 
not endure. After Akhenaten’s death 
in 1336 BCE, the cult that he had 
established faded from prominence, 
and Egypt returned to the worship 


















 Building  
a biobank
… a million veterans at a time
By Bruce Fellman | Greg Hall Illustration
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The exhortation to “enlist” wasn’t as dramatic as that 
of the famous “I Want You” poster featuring a red-, 
white-, and blue-clad Uncle Sam, but William Koob, 71, 
a seaman’s apprentice in the early 1960s, found the call 
almost as compelling. Koob, a bank auditor, was semi-
retired and working at the VA Connecticut Healthcare 
System campus in West Haven when he heard about an 
initiative called the Million Veteran Program (MVP). 
Launched by the Department of Veterans Affairs in 
2011 and co-directed by a Yale faculty member and a 
School of Medicine alumnus, the MVP hopes to recruit 
a million veterans over the next five to seven years. 
Genetic information and electronic health histories of 
that “mega-cohort” of vets will reside in an enormous 
biobank for scientists and clinicians exploring the con-
nections among genes, the environment, military ser-
vice, and disease. 
To date, said John Concato, M.D., M.S., M.P.H. ’91, 
professor of medicine and one of the project’s two 
principal investigators, nearly 350,000 veterans have 
signed up. Koob was one of them.
Building a biobank
“All MVP required was giving a blood sample, allowing 
my VA health record to be accessed, and filling out health 
questionnaires—and I quickly realized how valuable this 
information could be,” said Koob. “It was another oppor-
tunity to serve, and I was happy to contribute.”
The project, it turns out, is not the only endeavor 
looking for a million good men and women. As part of 
his 2016 budget, President Barack Obama announced 
in January that he wanted to invest $215 million to cre-
ate the Precision Medicine Initiative (PMI): a massive 
biobank—compiled from both emerging and existing 
databases (possibly including data from the MVP)—of 
genetic information and electronic medical records of a 
representative sample of U.S. citizens, a million strong. 
None of the information an individual provides, 
including the fruits of the DNA samples, goes into the 
veteran’s personal medical record. Instead, this nation-
wide “big data, big science” effort will allow researchers 
and clinicians “to better identify those at risk of getting 
a disease, those who might be prone to do worse with 
that particular ailment, and what medications might 
work best as treatment,” said Concato. “This is the 
promise of personalized medicine, and MVP stands to 
greatly improve our ability to provide it.”
ex pl or i n g th e gen o mic un iv er se
It’s too early to know what discoveries might be made, 
say Concato and the other principal investigator,  
J. Michael Gaziano, M.D. ’87, M.P.H., a professor of 
medicine at Harvard. Advances in understanding  
the interplay of genes and such illnesses as cancer,  
diabetes, and heart and circulatory problems, and  
such mental illnesses as service-related post-traumatic 
stress disorder (PTSD) are possible long-range pro- 
gram benefits.
“Just like the Hubble Space Telescope opened up 
ways of seeing the universe that Earth-bound tele-
scopes couldn’t provide, we think that MVP will allow 
us to explore the genomic universe,” said Gaziano, 
scientific director of the Massachusetts Veterans 
Epidemiology Research and Information Center, chief 
of the division of aging at Brigham and Women’s 
Hospital, and director of the VA Boston Healthcare 
System’s Geriatric Research and Education Center.
The MVP is one of several similar efforts around the 
world, among them biobanks in the United Kingdom 
and China, each of which has about 500,000 par-
ticipants, and at Vanderbilt University and Kaiser 
Permanente, which include about 175,000 and 200,000 
people, respectively. The MVP, if it meets its target, will 
be the largest among them.
All these efforts link at least two streams of genetic 
and medical data; the MVP links three. The first is 
genomic information gleaned from different DNA 
sequences: general genotyping; the sequencing of just 
the coding part, or exome, of the genome; or, in a small 
number of cases, whole-genome sequencing. The sec-
ond stream includes health and treatment information 
from each vet’s electronic medical record. The third 
part, unique to the MVP, is a health and lifestyle survey 
that includes questions about military service which 
will give researchers a better understanding of possible 
genetic underpinnings of conditions like PTSD that 
might affect people in the armed forces.
   Michael Gaziano // 
 “Just like the Hubble Space  
Telescope opened up ways of seeing  
  the universe … we think that  
 MVP will allow us to explore  
   the genomic universe. ’’The PMI, said the president, could “lay a foundation for 
a new era of lifesaving discoveries.” (Richard P. Lifton, 
M.D., Ph.D., chair and Sterling Professor of Genetics, 
has been named co-director of the PMI.)
The president’s initiative, if funded, would allow 
researchers to cull genetic secrets about the origin 
and development of physical and mental disorders—
insights that might lead to more custom-tailored and 
cost-effective treatments, particularly for cancer. The 
MVP, while its goals are similar, is targeted toward 
a more specific population—a group whose “can do” 
attitude and eagerness to enlist is typical, said Concato, 
who directs the VA’s Clinical Epidemiology Research 
Center in West Haven and has conducted extensive 
research on prostate cancer epidemiology and screen-
ing. “When you consider that this project is not going 
to benefit any of the participants directly,” he said, 
“their altruism is very impressive.”
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“MVP couldn’t have been built without the existing 
VA research infrastructure,” said Concato, who, with 
Gaziano, directs a staff of about 20 in West Haven and 
Boston, with key support from the Office of Research 
and Development in Washington, D.C.
One key to the program’s eventual utility is the VA’s 
reach: data are being collected at about 50 VA health care 
facilities around the country, each of which has two staff 
members dedicated to the MVP. Another is the avail-
ability of its pioneering electronic medical record, which 
can look backward and forward in time and follow vets 
wherever they live. A third aspect is data security—the 
VA made security the highest priority from the moment 
it started its EMR implementation. Last, recent develop-
ments in information technology, from automated bios-
torage data retrieval to computer analytic capabilities, 
allow researchers to manage massive amounts of data.
“Maybe the biggest enabling technology is having a 
chip that allows us to do cheap genetic testing,” said 
Gaziano. “We can now look at the genetic variation in 
about 750,000 places on a person’s genome for $75—that’s 
$52 for the chip and the rest for processing—and this abil-
ity to generate data, coupled with the information we’ll 
get from hundreds of thousands of vets, will let us start 
to answer questions we couldn’t have even asked before.”
One area of interest is an aging population. “We 
hope that MVP will be a pluripotent resource that can 
be used by researchers and providers to look at how 
to best deal with that group, from studies of frailty 
to understanding variations in medication-related 
enzyme metabolism,” said Gaziano. 
at  th e beg in n in g o f  a  re vo l ut i o n
Like Concato, Gaziano is no stranger to big-data projects. 
“I’ve been working in the large cohort business since I 
arrived at Brigham and Women’s in 1988,” he said. He’s 
had leadership and research roles in the Brigham and 
Women’s-based Physicians’ Health Study, which has fol-
lowed a cohort of more than 30,000 doctors in the United 
States to examine a variety of health questions, as well as 
the Nurses’ Health Study and the Women’s Health Study, 
both of which are affiliated with Brigham and Women’s 
and have enrolled cohorts of more than 100,000.
“While it builds on earlier work,” Gaziano said of 
the MVP, “it’s really something new.”
Early epidemiological studies were primarily descrip-
tive and involved small numbers of subjects or issues, 
such as the relationship of smoking to lung cancer. The 
famous Framingham Heart Study (FHS) in Massachusetts 
has since 1948 tracked 5,000 adults to ask fundamental 
questions about the epidemiology of cardiovascular dis-
ease. The FHS used multivariate computer modeling to 
examine the impact of a half-dozen risk factors.
But with 20,000 to 25,000 protein-coding genes 
in the human genome, a cohort needs hundreds of 
thousands of people so that scientists can determine 
“how genes interact with other genes and environmen-
tal factors to contribute to health and disease,” said 
Gaziano. “There are enormous numbers of variables, 
so we need mega-cohort studies like MVP to solve the 
signal-to-noise problem that genetics gives us. We’re at 
the beginning of a very exciting revolution.”
Two “alpha” studies have begun testing the bio-
bank’s ability to deliver useful information. Concato, 
Gaziano, and their colleagues have mined the database 
for mentally healthy vets who can serve as a control 
group for comparison with 9,000 vets with schizo-
phrenia or bipolar disorder. “The pending genomic 
analyses can advance our understanding of the eti-
ology of, and treatments for, two major psychiatric 
disorders,” the researchers wrote last year in the 
American Journal of Medical Genetics.
The second alpha test, co-directed by Joel Gelernter, 
M.D., the Foundations’ Fund Professor of Psychiatry 
at Yale, is using the biobank to find a cohort of vets 
with PTSD to compare with an MVP-assembled con-
trol group without the disorder. The hope is to identify 
genes that increase the risk of this often-devastating 
condition and to develop more effective methods of 
detecting and treating it.
Last year, MVP leaders issued a nationwide call  
for proposals, said Concato. About 20 have survived  
the first review round, and those approved will inves-
tigate an array of topics from heart disease and lung 
cancer to mental health disorders and problems  
with water metabolism. Funding decisions will be 
made later this year.
“It’s important to remember that MVP is an infra-
structure project,” said Concato. “Our role is to help 
design the program so that researchers can use the  
biobank effectively, securely, and ethically, and  
have the right information available to ask the right 
questions.” /yale medicine
Bruce Fellman is a freelance writer in North Stonington, Conn.
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 Whispers on the medallion,  
  the Society of Wu,  
and Frisbee on the lawn
WHAT DO YOU HAVE TO DO to get into the School of Medicine? 
According to Dan Okin, a fourth-year medical student, a super-
stition handed down by students directs you to the medallion 
beneath the rotunda in the Cushing/Whitney Medical Library—
where you stand and whisper your name and the phrase “Please 
let me in!” Thanks to architectural magic, they’ll hear you in the 
admissions office, which once occupied space above the rotunda.
“Our tour guides on interview  
day have the applicants stop in the  
center of the rotunda and say a  
few words to hear the mystical 
echoes,” said admissions director 
Richard A. Silverman.
If you ask alumni of the School 
of Medicine which traditions they 
remember best, they often mention 
venerable and well-established ones 
first—donning a white coat for the 
first time; honoring donors who 
willed their bodies to the anatomy 
lab; or raising money for the home-
less in an annual auction. But 
quirkier traditions, customs, and 
habits have appeared through the 
years at Yale Med, too. Passed down 
from student to student, these 
activities continue to evoke fond 
memories. Some have survived; 
some haven’t, though we don’t 
always know why.
For a time, students would sneak 
into the Brain Room, locked deep 
within a subbasement of Harkness 
Hall. A historic collection of brains 
preserved by neurosurgery pio-
neer Harvey W. Cushing, M.D., 
was moved there in 1979, along 
with haunting photographs of his 
patients. The collection was forgot-
ten for decades except by students 
in the know, who would break the 
lock or kick in a door panel to get in, 
then add their names to a graffiti-
like sign labeled “Brain Society.” 
Brain Room expeditions ended 
after the collection was spruced up 
and moved in 2010 to the Cushing 
Center, a dedicated space within the 
medical library.
Some student customs were very 
much of their time. In the late 1950s, 
recalls Malin Dollinger, M.D. ’60, 
students sought birth-control 
advice from ob/gyn fellows living 
in Harkness dormitory. (Condoms 
were then illegal in Connecticut.) 
He and his classmates used the 
dormitory lawn to play with a 
newly invented toy, the Frisbee. 
Years later, Jilda N. Vargus-Adams, 
M.D. ’95, and her class gamboled on 
a Wham-O Slip ’n Slide there after 
exams. (A 1993 national recall, with 
reports of quadriplegia in adults too 
tall to dive onto the toy, may have 
dampened enthusiasm for the slide.)
Alcohol has given rise to tradi-
tions both raucous and not. In the 
1990s, for instance, the Society of 
Wu (why it was so named has appar-
ently been lost to the ages) held a 
keg party in the Harkness basement 
just before exams. “The Yale system 
would dictate that you not take tests 
too seriously—surely you could go 
and partake in the Society of Wu 
the night before,” Vargus-Adams 
explained. (The Society seems 
to have mysteriously disbanded 
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before this writer matriculated 
in 2000.) The same philosophy 
invested Thursday night dances 
at the Graduate and Professional 
Students Center at Yale, also known 
as GPSCY. After late nights at GPSCY, 
she recalled, whether from fatigue 
or hangovers, attendance and 
energy were low at Friday morning 
anatomy lab.
More prosaically, Dollinger’s 
classmates volunteered for paid 
studies at the Yale Center of Alcohol 
Studies on the main campus. They 
had to phone for rides back to the 
medical campus when they became 
too drunk to walk. That tradition 
presumably ended when the center 
relocated to Rutgers in 1962.
Harkness wasn’t the only locus 
of party culture. In the early 2000s, 
the Pink House, an institution of 
sorts in the East Rock neighbor-
hood that housed a revolving and 
brotherly clan of medical, law, and 
physician associate students, hosted 
monthly rotation-switch parties. 
Alas, Roberto Lugo, M.D. ’04, who 
lived in that house, noted sadly on 
a recent reunion visit that it is no 
longer pink.
Yale Med’s longest-standing  
tradition, of course, is the Second- 
Year Show. Begun in 1949, it has bur-
geoned into a satirical extravaganza; 
the camaraderie and dedication it 
inspires make it the cherry on top of 
the Yale system. What few students 
these days know, though, is that the 
show began as a fourth-year activity. 
(The second-year show arose in the 
mid-60s; by the end of that decade, 
the fourth-years ceded the stage.)
The timing of the fourth-year 
show had its advantages, explained 
Victor A. Altshul, M.D. ’60. “We 
gave it just before graduating, so 
that the attendings we were lam-
pooning couldn’t retaliate,” Altshul 
recalled. “And boy, did we ever give 
it to them.”
















L ONG B E FOR E A N YON E DI S C OV E R E D DNA, chromosomes, or genes,  
humans had figured out something important about the world around us. 
When we turned from hunting and gathering our food to growing and  
raising it, we realized that we could breed plants and animals to bring out 
desirable traits. Wild grasses became wheat under human cultivation; we  
also domesticated and bred cows, pigs, and sheep to produce food, leather, 
and wool. And we also noted similarities between parents and offspring 
without knowing what causes these similarities. The concept of heredity  
preceded the science of genetics, but it is genetics that explains why all liv- 
ing species carry inherited traits and qualities. This timeline lists some of  
the key advances in thinking about heredity and genetics.
 H istory  
of heredity
By John Curtis | Jennifer Stockwell Illustrations | Benjamin Hecht Photos
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During the Neolithic era, about 
12,000 years ago, as humans 
move from hunting and gathering 
to growing their food and raising 
animals, they learn to breed 
desirable traits into wild grasses 
(1) and domestic animals.
In the fifth century B.C., Hip-
pocrates (2) speculates that 
“seeds” are produced by various 
body parts and transmitted to off-
spring at the time of conception.
Theophrastus (3), a Greek scholar 
of the late third century B.C., 
who studied under Aristotle 
and is considered the “father 
of botany,” proposes that male 
flowers cause the ripening of 
female flowers.
Aristotle (4) proposes in the 
fourth century B.C. that male 
semen and female menstrual 
blood mix at conception and 
that offspring receive traits from 
both mother and father.
Abu al-Qasim (5), an Arab physician 
from about A.D. 1000, who is 
considered the father of modern 
surgery, describes the heredi-







William Harvey (6), a seventeenth- 
century London physician,  
wonders why offspring some-
times resemble the father, 
sometimes the mother, and 
sometimes progenitors both 
maternal and paternal.
During the late seventeenth 
century, the Dutch lensmaker 
Antonie van Leeuwenhoek (7) 
describes “animalcules” in the 
semen of humans and animals.
Around 1800 the notion of 
heredity enters debates among 
physicians, animal breeders (8), 
and naturalists, and becomes a 
fundamental concept of biology.
The Austrian monk Gregor Mendel 
(9) describes patterns of inheri-
tance in peas in the mid-1800s, 
but his theories are ignored, to be 
rediscovered only in 1901.
In the mid-nineteenth century, 
the English naturalist Charles 
Darwin (10) proposes the theory of 
evolution, with natural selection 
and heredity as its mechanisms.
In 1869 a Swiss physician, Fried-
rich Miescher (11), discovers a 
microscopic substance in pus 
obtained from discarded surgi-
cal bandages. He isolates DNA 
from those samples and calls it 
“nuclein” because it resides in the 
nuclei of cells.
Hugo de Vries (12), a Dutch bota-
nist and geneticist, postulates in 
1889 that “inheritance of specific 
traits in organisms comes in 
particles,” and calls the particles 
“(pan)genes,” a term that would 











In 1902–03, Walter Sutton (13), 
an American physician, and 
Theodor Boveri (14), a German 
biologist, independently propose 
the chromosome theory of in-
heritance: chromosomes, which 
segregate in a Mendelian fashion, 
are hereditary units.
William Bateson (15), an English 
geneticist, coins the term gene-
tics in 1905.
In 1931, Barbara McClintock (16),  
an American pioneer in cyto-
genetics, provides the first 
proof that genes are physically 
positioned on chromosomes.
In 1944, Oswald T. Avery (17), 
Colin MacLeod (18), and Maclyn 
McCarty (19) conducted an 
experiment at the Rockefeller 
Institute that isolated DNA as the 
substance that causes genetic 
transformation.
James Watson (20), Francis Crick 
(21), Maurice Wilkins (22), and 
Rosalind Franklin (23) elucidate 
the structure of DNA at the Uni-
versity of Cambridge in 1953.
2001–2003: The first draft se-
quences of the human genome 
are released by the international 
Human Genome Project and 
Celera Genomics in February 
2001; two years later, the Human 
Genome Project is considered 
complete, with 99 percent of the 











 So you’ve decided to  
become a doctor
A PPE N DIC I T I S L A N DE D X I A NG (AV E L I N E) L I  in the emergency 
room during her junior year at Bowdoin College, where she was 
majoring in biochemistry. Her parents, both physicians, were 
living halfway around the world in China and she was frightened 
and unsure about what was happening. After the appendectomy, 
complications required a second surgery and two more weeks 
in the hospital. During her recovery Li gained firsthand insights 
into the needs of patients. Prior to her illness, she’d been explor-
ing medicine to see whether she wanted to become a doctor. 
Becoming a patient helped confirm her decision.
While Li was recovering, Nidharshan 
Anandasivam, also a college junior, 
was studying biomedical engineer-
ing at MIT and exploring volun-
teer opportunities to see whether 
medicine was in his future. Having 
injured his ankle several times while 
playing basketball, Anandasivam 
Fascinated by high school biol-
ogy and the human body, Li’s 
interest in medicine grew as she 
sought opportunities to engage 
patients and observe the physi-
cian’s role. During high school she 
volunteered at the Veterans Health 
Administration and worked with a 
physician on reducing patient wait-
ing times. “That experience had a 
big impact,” she said. “Seeing how 
happy patients were to see their 
doctor and observing the mutual 
trust involved in the doctor-patient 
relationship was inspiring.” In 
college, she volunteered at a local 
hospital and the American Cancer 
Society. “Each new volunteer expe-
rience confirmed that I wanted to 
become a doctor,” Li explained.
Li’s maternal grandfather had 
been a doctor and her maternal 
grandmother had been a nurse. 
But her father, a neurologist, and 
her mother, a pediatrician, had no 
expectation that Li would go into 
medicine. In fact, because of the 
consuming nature of the profession, 
they initially tried to dissuade her. 
Li didn’t grow up seeing her par-
ents working with patients, because 
they lived in Canada and the United 
States, where neither parent was 
licensed to practice. They instead 
did genetics research, and when 
Li started college they returned to 
China to practice medicine. During 
visits to China, Li observed the very 
limited time her parents could spend 
with their patients. She valued the 
patient-physician relationship and 
was determined to practice medicine 
in a different way. “China’s large 
population means my parents don’t 
have time to do what I’m learning at 
wondered whether he would be able 
to integrate his passions for sports, 
health, and science into a career. His 
physician parents had encouraged 
him to pursue his interests in college 
and see where they led.
What influences a child of physi-
cians to choose a career in medi-
cine? For Li and Anandasivam, 
students in the Class of 2018, a 
future in medicine was not a fore-
gone conclusion even though their 
parents are physicians.
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Yale—the patient-centered interview,” 
she explained.
Anandasivam’s family is from Sri 
Lanka, but he grew up in Rancho 
Viejo, Texas, where his father is a 
nephrologist and his mother is an 
internist. During high school, strong 
interests in math and physics pointed 
him toward engineering. But his 
college classes, research, and vol-
unteer activities increasingly pulled 
him toward medicine. Anandasivam 
carefully chose volunteer opportu-
nities that exposed him to differ-
ent aspects of medicine, including 
working as an EMT Basic with MIT’s 
EMS service and participating in the 
MIT MedLinks program, a dorm-
based peer-to-peer health advocacy 
group. He also worked with LIFT, a 
community service program, where 
he enjoyed helping people solve 
problems and find resources. “My 
experiences in college serving the 
community were the driving forces 
in my choice,” he explained.
Anandasivam said that his par-
ents and especially his grand- 
mothers, who lived with his family 
and helped raise him and his younger 
brother, modeled the importance 
of service. “They were ‘service first’ 
people and that had a big effect on 
me,” he said. As he experienced the 
service side of medicine in concert 
with the intellectual side, it became 
clear that medicine was a good fit.
The influences that led Li and 
Anandasivam to choose medicine 
were multifaceted. They enjoyed 
the intellectual challenges of medi-
cine and valued serving others. 
For Li, meeting outstanding clini-
cians—including the surgeon who 
performed her second surgery—also 
confirmed her decision. His engag-
ing bedside manner provided a role 
model for the type of doctor she 
wants to become. Anandasivam 
said his parents’ enthusiasm for 
their profession helped him see 
how rich a life in medicine could  
be. “I would’ve been less enthusi-
astic about it if my parents’ work 
compromised their ability to  
perform their other important 
responsibilities,” he added. “But 
they spent a lot of time with us and 
showed us that it’s possible to have 
an engaging career and fulfill your 
role as a parent and spouse.”
—Katherine L. Kraines
Nidharshan Anandasivam and Xiang 
Li are both children of doctors. How 
much did their parents infl ence 











 When a gene 
goes awry
Medical and genetic sleuthing  
unravel the mystery of an infant’s  
death and a father’s fevers
By Jill Max | Harold Shapiro Photos
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When Mustafa K. Khokha, M.D., first saw the Drewniak 
baby in the summer of 2012, he was worried. The baby 
boy, first treated at Norwalk Hospital, had a high fever 
and severe diarrhea that was getting worse. Clinicians 
at Yale-New Haven Hospital’s Pediatric Intensive Care 
Unit were frantically trying to keep up with fluid 
losses. Infection, the most likely culprit, had been 
ruled out. Khokha, associate professor of pediatrics 
(critical care) and of genetics, wondered whether an 
underlying genetic cause would explain the baby’s 
condition, and called Richard Lifton, M.D., Ph.D., chair 
and Sterling Professor of Genetics. Genome sequencing, 
Lifton felt, might yield clues to the infant’s ailment. 
Both Lifton and Khokha thought that the baby might 
have a new genetic mutation—a de novo mutation—
since both of his parents were healthy.
They used high-throughput exome sequencing to  
analyze the 21,000 protein-coding genes in the 
genomes of the baby and both his parents. Meanwhile, 
Neil D. Romberg, M.D., assistant professor of pediatrics 
Susan Kazmierczak, Neil Romberg, 
Richard Lifton, and Mustafa Khokha 
were part of a team of clinicians  
and scientists who determined that 
a defective gene was behind a  
family’s health problems.
When a gene goes awry
(immunology), examined the baby for a rash. Romberg 
recognized it as the first sign of a massive immune 
response, and lab tests indicated that the baby had wide-
spread inflammation. “Inflammation in the absence of 
infection is usually a genetic problem,” said Romberg.
The Yale Center for Genome Analysis rushed the 
sequencing and analysis. Completed in just a few 
days—a heroic effort—test results arrived the day after 
the 3-week-old baby died. The analysis found no de 
novo mutations that explained his illness.
A few days after the funeral, Erik Drewniak was still 
reeling from the loss of his infant son when he came 
down with a fever. He didn’t think it was anything to 
worry about. All his life he had had fevers that spiked 
as high as 106 degrees. But this time the fever persisted 
and he was having difficulty breathing. Concerned 
about pneumonia, he went to the emergency room. At 
Norwalk Hospital, Drewniak’s condition deteriorated. 
He went into respiratory failure and was put into a 
medically induced coma so that he could be intubated. 
Soon afterward, he was in intensive care at Yale-New 
Haven Hospital where tests showed he was suffering 
from inflammation and hemorrhaging of the bowels, 
lungs, and brain. His condition was serious, but he 
improved and went home nine weeks later.
a c l ue in  a  r a n d o m mut at i o n
With every sequencing of a patient’s genome, new, 
previously unseen protein-altering variants in genes 
emerge. These random mutations are due to variation 
in the human population. When Romberg suggested 
that the baby might have had an autoinflammatory 
disease, Lifton invited him to his lab to look at a list of 
variants. Romberg recognized a mutation in NLRC4, a 
gene involved in the innate immunity pathway—the 
first line of defense in the body’s response to infec-
tion—that could contribute to disease, although it had 
never been shown to have such an effect. That same 
day, while gathering information about the baby 
from Norwalk Hospital, Lifton’s research coordinator 
learned that Erik Drewniak was hospitalized with a 
severe illness. For Lifton, that was an “aha” moment.
“We recognized at that point that the variant in NLRC4, 
which was shared between the father and the baby, might 
link their diseases,” he said. It turned out that Drewniak 
and his infant son shared a genetic mutation causing an 
illness that had never before been described.
Advances in genomic sequencing technology, com-
bined with clinical expertise and biochemical analysis, 
allowed Yale doctors to identify the mutation, home 
in on the pathway it affected, and devise a personal-
ized therapeutic strategy that saved Drewniak’s life. 
Using whole-exome sequencing to diagnose diseases 
is increasingly proving to be both useful and practi-
cal. Five years ago it would have cost about $10,000 to 
do the exome sequencing performed on the Drewniak 
family; today it costs about $500. Not surprisingly, 
this service is rapidly expanding. Last year, Yale 
sequenced about 500 patients; this year about 1,000 
will be sequenced. The Drewniaks’ experience is just 
one example of the ways in which personalized medi-
cine, which is being supported by President Obama’s 
recently announced Precision Medicine Initiative, is 
gaining ground.
pa s s in g o n a  gen e
To confirm that the Drewniaks’ illnesses were caused 
by the newly identified mutation, the Yale team 
sequenced other family members, including Erik’s 
parents and two children who are half-siblings of his 
infant son. While his parents and daughter do not have 
the NLRC4 mutation, the sequencing showed that his 
son, now 7, does. Like his brother, he was hospitalized 
as an infant, although in his case it was due to kidney 
failure. Like his father—who was also hospitalized as 
a baby for a fever and severe diarrhea—he suffers from 
periodic high fevers. The mutation was in fact de novo, 
but it first occurred in Erik Drewniak, who passed it 
on to two of his children. His young son has a 50/50 
chance of passing it on to his offspring.
Once a genetic mutation emerged as the likely cause 
of disease in three Drewniak family members, the 
next step was to understand how a single change in 
this particular protein code could wreak such havoc. 
“Exome sequencing by itself is not the solution,” said 
Khokha. “It’s just the first step.”  Romberg enlisted 
Barbara I. Kazmierczak, Ph.D., M.D., associate profes-
sor of medicine (infectious diseases) and of microbial 
pathogenesis, who had been studying NLRC4 in mice. 
NLRC4 belongs to a group of intracellular proteins 
that react when bacterial toxins breach the cell wall.  
Kazmierczak and Romberg’s research showed that the 
mutated NLRC4 protein activates a powerful inflam-
matory pathway that sent the Drewniaks’ immune 
systems into overdrive, even though no bacterial 
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infection was present. “Their system is always on when 
it should be off,” said Kazmierczak.
Today, Erik Drewniak is healthy, as he has been for 
much of his life. “It didn’t affect me when I was grow-
ing up,” he says of his illness. He played in bands and 
was on the tennis team in high school, missing only 
an occasional event because of a fever. His son is also 
relatively healthy. “He does kung fu and other typical 
kid stuff,” said Drewniak. But the mutation they share 
causes a constant state of inflammation in their bodies 
that can become dangerous.
When Erik Drewniak was hospitalized in 2012, 
Nikolai A. Podoltsev, M.D., Ph.D., assistant professor of 
medicine (hematology), treated him for what appeared 
to be hemophagocytic lymphohistiocytosis (HLH), 
another disease in which the immune system becomes 
overstimulated. Drewniak’s condition, while differ-
ent, closely resembles HLH and responded to powerful 
anti-inflammatory medication and immunosuppres-
sants, which are used to treat HLH.
un d er st a n di n g th e di sea se
Now that Podoltsev and Romberg (who treats 
Drewniak’s son) know the mechanism of this disease, 
they are better equipped to treat it in the future. “Of 
course it’s easier to manage him going forward under-
standing what we’re dealing with,” said Podoltsev. The 
Drewniaks’ care involves managing the inflamma-
tion and monitoring symptoms. The mutation causes 
production of high amounts of cytokines—in this case 
interleukin 1 beta—that cue the immune system to start 
reacting to an infection, so interleukin 1 inhibitors could 
be useful if either of them experiences a flare-up.
Beyond the therapeutic implications of these dis-
coveries, the ability to pinpoint the cause of mysterious 
illnesses is invaluable. “When a baby dies of diar-
rhea, it’s very disturbing because it doesn’t happen 
in this country,” said Khokha. “It feels like a failure.” 
Being able to tell his parents why their baby died pro-
vided some solace. Fortunately for families like the 
Drewniaks, diagnosing rare genetic illnesses is becom-
ing more common. “We’ve gotten to the point where 
genetic sequencing is fast enough and cheap enough 
and we’ve done enough of it, that this is no longer sci-
ence fiction,” said Romberg.  
Erik Drewniak and two of his 
children suffered from unexplained 
fevers. Doctors and scientists at 
Yale discovered the cause—a de 
novo genetic mutation.
“It’s clear there will be many more cases like this 
one,” said Lifton. Of the 21,000 protein-coding genes 
in the human genome, he said, scientists know what 
happens when about 3,000 of them are mutated. 
“When I’m asked what remains to be done, the answer 
is practically everything.” Researchers are begin-
ning to tackle this undertaking. The Yale Center for 
Mendelian Genomics is one of three national centers 
created by the National Institutes of Health to try to 
understand the genetic causes of diseases like the one 
in the Drewniak family. The center has identified about 
250 new disease genes since it was established in 2012.
Meanwhile, Khokha and his colleagues often 
see children with birth defects or unexplained ill-
nesses that they are unable to diagnose. A new pro-
gram, Pediatric MAP, supported by the Yale School of 
Medicine, the Yale Center for Clinical Investigation, 
and Yale-New Haven Hospital will allow them to carry 
out the research that was done for the Drewniaks on 
a broader scale. The hope is that by formalizing the 
program, Yale doctors will be able to provide answers 
for these families by identifying genetic mutations 
and unraveling their biology with the ultimate goal of 
developing new therapeutic approaches.
For Drewniak, the knowledge of what caused  
his infant son’s death is empowering. “Genetics is some-
thing you can latch on to as a definite explanation,” said 
Drewniak. “It’s not the environment, it’s not something 
you did or didn’t do, it’s genetics. It made me understand 
not just him, but all three of us. Everything just came 
together and now it all makes sense.” /yale medicine
Jill Max is a freelance writer in Trumbull, Conn.
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 Refl ctions  
of a neuroscientist
I COULDN’T HAVE DESIGNED A BETTER EXPERIMENT IF I’D TRIED. 
I am a neuroscientist and I am the father of 2-year-old  
triplets—two identical and one fraternal. As a professor at Yale 
University, I spend most of my time designing experiments, 
researching or teaching about the brain and the nervous system. 
The rest of my time I spend surrounded by my three daughters. 
To understand the dynamics in my household, think terrible-
twos, and then cube it.
In the quiet sanctity of my lab,  
we study how the nervous system  
forms during development. In 
all animals, from humans to the 
tiny worms that we use for our 
experiments, neurons connect to 
each other and form circuits that 
The New Haven home of Daniel Colón-Ramos, Ph.D., his wife, Emily 
Wang, M.D., assistant professor of medicine, and their triplet daugh-
ters is a Tower of Babel. The 4-year-olds Alexandra, Beatriz, and  
Caysani speak Spanish among themselves, with their dad, and with 
their nanny, and speak Mandarin with their mom. Mom and Dad 
speak to each other in English, and each speaks a bit of the other’s 
native tongue. Watching how his daughters play and communicate 
led Colón-Ramos, associate professor of cell biology, to write an 
article for the TEDBlog in December 2012, when the girls were toddlers. 
In “On nature versus nature: A neuroscientist knee-deep in diapers  
reflects,” he described the lessons he’s learned from his daughters, 
how they’ve changed his brain, and the futility of the debate over 
nature versus nurture. Since he wrote the article, Colón-Ramos tells 
us, what he said then remains true today.
underlie behaviors. Genes (made 
of DNA) underpin many aspects of 
development—from how our brain 
forms to the color of our eyes.
My identical twin daughters 
look identical because they share all 
of their DNA; they are essentially 
clones of each other. They teethed 
exactly the same day, and their 
funky hairstyle is not the result of 
a visit to a stylist, but of genetics. 
Their personalities, however, are not 
identical. Not even close. The twins’ 
personalities, which share 100 per-
cent of their DNA, are curiously 
more similar to that of their frater-
nal sister than to each other.
That certainly came as a surprise 
to me. After all, argue all you want 
about nurture, but behaviors do 
have genetic underpinnings in the 
animal kingdom. Take reptiles; soon 
after hatching from its egg, a baby 
crocodile can hunt dragonflies with 
the same dexterity that its parents 
can hunt antelopes. Who taught the 
baby crocodile to hunt? Genes.
I reflected about this a lot as 
I held my newborn daughters in 
the nursery room of the hospital. 
Human brains at birth do not appear 
nearly as impressive as a reptil-
ian brain. For crying out loud, the 
tiny nematodes we use in the lab for 
our experiments can move around 
better at birth than a human baby! 
Newborns appear as blank slates. 
Are we really a tabula rasa? What 
are the roles of nature (genes) and 
nurture (our environment) in the 
development of our brains, in mak-
ing us human?
My epiphany came with the 
first visit to the pediatrician. She 
closely monitored our daughters 
as they met, in unison, one devel-
opmental milestone after the other. 
As a neuroscientist, I knew what 
this timely emergence of complex 
behaviors meant: it is a hallmark 
of preprogrammed brains. But our 
preprogrammed brains are not for 
hunting dragonflies. The evolution-
ary pressures that have shaped our 
brains are different from those that 
have shaped the brains of swamp-
bound reptiles.
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We are born into complex soci-
eties and quickly have to learn to 
negotiate our place within them. My 
three kids, the ones playing with 
my iPhone, are the same species as 
my ancestors, who 40,000 years ago 
were figuring out how to sharpen a 
rock and fit it into a spear. The Homo 
sapiens brain is wired in a very par-
ticular way: to allow us to connect to 
other human brains.
Our home is testament—a cross 
between the Tower of Babel and a 
Univisión soap opera. It is filled with 
sound, from the tonal Chinese my 
wife has taught the triplets to the 
slurred Puerto Rican Spanish they 
have learned from me. During the 
past two years I have witnessed how 
each of my daughters has master-
fully decoded the complex rules of 
language and social interactions in 
three very different and overlap-
ping cultural contexts, and simulta-
neously. They confidently navigate 
between languages in a way that 
sometimes neither my wife nor I can 
follow. Chatty conversation and fes-
tive giggles are only one disagree-
ment away from despair and temper 
tantrums over a train set, a Crayola, 
or a dinosaur shirt. But most melt-
downs end with hugs, sometimes all 
three at the same time, as they can’t 
wait to make up.
My daughters’ desire to connect 
is not just cute, it’s a matter of sur-
vival. So important is our need to 
connect to other human brains that 
extreme cases of child neglect have 
resulted in developmental problems 
not unlike those seen for mental 
retardation. These extreme cases tell 
us something profound about the 
brain. It tells us that even in cases 
in which normal genetics prime the 
brain to connect to other brains, the 
absence of human input cripples 
brain development. Our brains need 
other brains to develop properly.
These seemingly delirious 
thoughts of a sleep-deprived sci-
entist are neither new nor original 
ideas. Today it is broadly accepted 
that trying to separate nature from 
nurture is as asinine as trying to 
debate whether a cake is made out of 
milk or flour. But this is important 
beyond a mere academic debate. In 
science, extreme cases are used to 
understand concepts. If no human 
contact during critical develop-
mental periods can cripple brain 
development, what are the conse-
quences of reduced stimulation due 
to a defective and underfunded edu-
cational system? The United States 
incarcerates more of its youth than 
any other country in the world—
what are the consequences of grow-
ing up in a prison? We are social and 
codependent animals—what are the 
hidden costs to our society when 
we ignore the “nurture” part of the 
human development equation?
The human brain has over 100 bil-
lion neurons—there are more neu-
rons in a single human brain than 
stars in the Milky Way. When a par-
ent stares at the lost, unfocused gaze 
of a newborn child, they are literally 
staring at a constellation of pos-
sibilities, at a brain primed through 
evolution to connect to other brains, 
to devour information, to adapt and 
to reach its potential. In truth, I’m 
highly trained, but not that special; 
we are all born scientists, and our 
brains are molded by our favorite 
subjects of study, other humans. 
And I have the perfect experiment 
to prove that—my brain, which has 
been transformed by my daughters.
—Daniel Colón-Ramos
Emily Wang and Daniel Colón-Ramos speak to each other in 
English. Wang speaks Chinese to their 4-year-old triplets, 
Alexandra, Beatriz, and Caysani. Colón-Ramos speaks to them 















 Man as  
industrial palace
 A view of the human body  
 in the Industrial Age
 By Christopher Hoffman
CLOCKWISE FROM TOP:
Fritz Kahn, a German 
gynecologist, conceived 
of a series of popular 
books, The Life of Man, to 
make the science of the 
human body accessible 
to a broad audience. Kahn, 
considered a pioneer in 
infographics, composed 
the text, and designed 
or approved ideas for the 
illustrations. In The Will of 
Mankind, Kahn provided a 
depiction of the functions 
of the mind and brain.
An earlier eff rt at illustrat-
ing the workings of the 
human body comes from 
a Japanese artist, Utagawa 
Yoshitsuna, in the mid-19th 
century. Model for Men’s 
Dietary Care, a polychrome 
woodblock print, shows a 
subject digesting a meal 
of fish and sake. As with 
Kahn’s illustrations, it uses 
the metaphor of workmen 
performing familiar tasks 
to demonstrate the actions 
of the internal organs. 
In Man as an Industrial 
Palace, Kahn depicted 
the human digestive and 
respiratory systems as a 
chemical plant.
OPPOSITE PAGE:
TOP A French advertis-
ing poster from the early 
20th century borrowed 
from Kahn’s imagery to 
advertise the benefi ial 
results of a popular laxa-
tive. It appeared around 
the time of Kahn’s post-
ers published with Das 
Leben des Menschen. 
BOTTOM From The Life of 
Man, a depiction of the 
human respiratory sys-
tem also uses the visual 
analogy of a factory.
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The nearly life-sized poster 
titled Der Mensch als 
Industriepalast (Man as an 
Industrial Palace) depicts 
the human body as a com-
plex machine, a wonder of 
the industrial age.
Workers stand at power 
plant-like control panels and 
operate the body’s central 
nervous and respiratory 
systems. Oxygen and carbon 
dioxide travel in automated 
bucket lines down pipes 
to and from the lungs. The 
heart’s chambers are a pair 
of pistons, the stomach a 
conveyor belt, and the spi-
nal cord a telephone system 
with switchboard operators 
directing calls.
The arresting image is the 
work of Fritz Kahn, M.D., a 
German gynecologist who 
in the 1920s wrote a series 
of popular books titled Das 
Leben des Menschen (The Life  
of Man) that strove to explain 
science and medicine to a 
broad audience. The colorful, 
intricately drawn diagram 
is one of three—all origi-
nally inserts in The Life of 
Man—displayed at the Harvey 
Cushing/John Hay Whitney 
Medical Library in January.
Largely forgotten until 
recently, Kahn’s books were 
famous for their detailed, 
innovative, and aesthetically 
pleasing illustrations, said 
Susan Wheeler, the medi-
cal library’s curator of prints, 
drawings, and historical  
posters. “I think he had an 
idea of making ideas hand-
some and accessible,” she said.
Today, Kahn is widely 
recognized as a pioneer of 
information graphics, the 
use of images and visual 
metaphors to convey infor-
mation and ideas. He is 
often mentioned in the same 
breath as the Austrian Otto 
Neurath, who at about the 
same time invented isotype, 
the communication of data 
through pictographic charts.
Both men did their most 
famous work in post-World 
War I Central Europe, a 
time and place of social and 
political upheaval as well as 
technological and artistic 
innovation. That ferment 
sparked “a fireworks display 
of new aesthetic form,” wrote 
Uta and Thilo von Debschitz 
in their 2013 book, Fritz 
Kahn. In the introduction 
to the von Debschitzs’ book, 
graphic design historian 
Steven Heller likens Kahn to 
astronomer Carl Sagan in his 
ability to make science acces-
sible to the ordinary person.
“The art of analogy was 
Kahn’s forte,” Heller wrote. 
“Kahn employed whatever 
visual trick he could cobble 
together for the end result: 
popular comprehension.”
The Life of Man series 
made Kahn Germany’s most 
famous popular science 
writer of the 1920s. A terrible 
artist, he commissioned  
others to render his ideas 
into illustrations.
Kahn, who was Jewish, 
fled Germany when the 
Nazis seized power. The new 
regime banned and burned 
his books. But in an ironic 
twist, Nazi authors plagia-
rized his work and illustra-
tions, adding chapters on 
supposed racial superiority. 
Kahn later lived in France, 
the United States—gaining 
entry with the help of fellow 
German Jew Albert Einstein—
Switzerland, and Denmark. 
He died in 1968, his work 
largely forgotten.
The other two Kahn posters 
displayed at the medical 
library are as fanciful as  
Man as an Industrial Palace, 
his most famous image. In  
one, an operator using a tele-
scope and control panels  
illustrates how the brain 
tells the finger to press a 
doorbell. In the other, a war-
ren of chambers containing 
conveyor belts, storage tanks, 
and other industrial devices 
demonstrates the circulation 
of blood and air through  
the body.
Wheeler said that the 
posters, donated to the 
medical library in the late 
1970s and shown here for 
only the second time, elic-
ited fascination and delight. 
“There’s a kind of awed 
response to [them],” she said. 
“Visitors ask the same kind 
of questions, which is who 
did them and what were they 
for? But everyone expresses 






























“We saw so many patients die 
of melanoma within a couple of 
months of phenomenal immu-
notherapies going into clinical 
investigation,” said LoRusso, 
who joined Yale Cancer Center in 
August 2014 as associate director 
of innovative medicine. “It isn’t 
over until it’s over, and we often 
don’t know what the next drug 
is going to offer.”
Among her accomplish-
ments, LoRusso heads one of 
the first multi-institutional 
investigator-initiated person-
alized medicine clinical trials, 
in collaboration with national 
melanoma leaders, as part of her 
role as co-leader of the Stand Up 
to Cancer/Melanoma Research 
 Bringing new cancer  
treatments to the clinic
»
I N M A N Y WAYS, Patricia M. LoRusso, D.O., has realized one of her main  
missions in life—bringing the latest therapies to people with advanced 
cancers through clinical trials. For many patients, a few months can 
make a difference and help them get to the next new treatment.
Alliance Melanoma Dream Team. 
She came to Yale from Wayne 
State University’s Barbara Ann 
Karmanos Cancer Institute, 
where she was director of the 
Phase I Clinical Trials program 
and part of the Eisenberg Center 
for Translational Therapeutics.
At Yale she sees her role as 
a mix of clinical research and 
translational medicine, in which 
she can apply her experience 
developing novel drug therapies 
and designing clinical trials.
For LoRusso, bringing novel 
therapeutics to the clinic is 
highly personal. She was still in 
high school when she lost her 
mother to cancer. A short time 
later, her father succumbed to 
lung cancer. Through her grief, 
LoRusso realized her life’s path—
to become a physician and help 
improve outcomes for people 
with cancer.
“It became a defining moment 
in my life,” said LoRusso, who 
has more than 25 years of exper-
tise in medical oncology, drug 
development, and early-phase 
clinical trials. “At the time my 
parents died, there weren’t good 
therapies, and I was determined 
to develop new, better drugs to 
treat cancer.”
Today, the Detroit native is 
internationally recognized for 
bringing promising early-stage 
anticancer therapeutics to the 
clinic, among them TDM-1, now 
known as ado-trastuzumab 
emtansine, or Kadcyla®. As a 
clinical investigator assisting 
Genentech in developing Kadcyla, 
she studied “such questions as 
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Patricia LoRusso, Yale 
Cancer Center’s new 
associate director of 
innovative medicine, 
sees her role as a mix 
















whether the drug impacts on con-
duction mechanisms of the heart, 
how it is dosed in patients with 
liver dysfunction, how it interacts 
with other agents in terms of tox-
icity and potential efficacy.”
Clinical trials, she said, have 
evolved in such a way that there 
is less distinction between Phase 
I and II trials. This means more 
targeted, tumor-specific thera-
pies are being studied and at ear-
lier stages. LoRusso and other 
researchers are seeking patients 
with specific tumor types as they 
“carry out clinical trials to answer 
pivotal clinical questions in 
anticipation of FDA submission 
and eventual approval of drugs.”
Most of the patients LoRusso 
and her team care for have 
recurrent cancers that have 
defied conventional treatments.
“It’s a huge motivator when 
you can help [extend the life of] a 
patient who would otherwise be 
dying of advanced cancer,” she 
said. Even more motivating are 
those occasions when she cannot 
help them at all. “You realize how 
much harder you have to work.”
But she sees the future as 
bright, thanks in large part to 
a greater understanding of the 
biology and genomics of the dis-
ease. “This is undoubtedly the 
most exciting time to be devel-
oping new cancer drugs, and 
we are making progress,” said 
LoRusso. “My mother would 
have had a much better progno-
sis and may actually have been 
cured of her disease had she 
been diagnosed in 2014 instead 
of 1970.”
LoRusso, who earned her 
doctorate in osteopathic medi-
cine at Michigan State University 
in 1981, lives in Hamden with her 
husband, Julian.  They have three 
(now adult) adopted children. 
“They are my best friends, and we 
have a lot of fun together.”
—Amanda Crowe
»
How an 18th-century 
doctor enticed a  
librarian to study the 
history of medicine
Melissa J. Grafe, Ph.D., likes to 
reach back in time to tell the 
story of John Archer, the first 
graduate of an American medi-
cal school program. Practicing in 
18th-century Pennsylvania, and 
confronted with a child whose 
symptoms resembled what we 
now call diphtheria, Archer 
discovered a treatment using a 
native American plant. A dose 
of Seneca snakeroot, a powerful 
emetic, allowed the suffocating 
child to breathe again.
Use of the treatment began to 
spread after Archer told his five 
physician sons and 35 apprentices 
about his successful experimenta-
tion with Seneca snakeroot.
“I started to delve into the 
story of this man, and his sons, 
and his apprentices,” Grafe, the 
John R. Bumstead Librarian 
for Medical History, said of the 
physician who was the subject 
of her dissertation at Johns 
Hopkins University. In 1768 
Archer became the first gradu-
ate of the School of Medicine of 
the College of Philadelphia, now 
the University of Pennsylvania. 
“His story is why I became inter-
ested in medical education and 
apprenticeship. People learn 
medicine in so many different 
ways. How does it play out in a 
family whose members are all so 
interested in medicine?”
Her interest in the history 
of medicine had begun earlier, 
during her undergraduate days 
at Ursinus College in her native 
Pennsylvania, when she read 
the Pulitzer Prize-winning 
A Midwife's Tale, by Laurel 
Thatcher Ulrich.
Now, Grafe pursues her inter-
ests in medical education and the 
history of medicine at work every 
day. As director of the Medical 
Historical Library, she helps 
students and scholars navigate 
its collections, housed within 
the Cushing/Whitney Medical 
Library. She curates exhibits 
that showcase materials from 
the library’s more than 140,000 
volumes, as well as thousands of 
manuscripts, drawings, prints, 
incunabula, and other items 
spanning every era of medical 
history. Recent exhibits range 
from the 16th-century anatomi-
cal drawings of Vesalius, some of 
which incorporate an ingenious 
lift-the-flap design not unlike 
what we see in children’s books 
today, to 1970s-era Technicolor 
posters highlighting the dangers 
of excessive drinking.
After college, Grafe worked  
at historical sites in Pennsylvania 
and North Dakota, curating 
exhibits, conducting tours, and 
How the Grinch Stole the 
Yale System!
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factor: the chance to be in the 
presence of the past's medical 
heroes. The library holds pieces 
from many scientific greats: 
Newton, Kepler, and Copernicus, 
to name a few.
“Can you imagine touching a 
letter written by Charles Darwin 
in 1859?” Grafe asked. It is this 
kind of irreplaceable experience 
a library can provide, one that 
can inspire a scientist to experi-
ment anew.
—Jeanna Canapari
Melissa Grafe’s doctoral 
dissertation on an 18th-
century Pennsylvania 
doctor sparked her  
fascination with the his-
tory of medical educa-
tion and apprenticeship.
working on community out-
reach and education. In North 
Dakota, where the distance  
to a hospital can be great, she 
also trained as an EMT. It was 
then, Grafe said, that “I be- 
came interested in how people 
heal themselves.”
Grafe completed her Ph.D. at 
Johns Hopkins in 2009 and then 
did postdoctoral work through 
the Council on Library and 
Information Resources. She was 
a librarian at Lehigh University 
when the position at the Medical 
Historical Library became open. 
She jumped at the opportunity. 
“This is a once-in-every-20-or- 
30-year position,” she said. 
“This is the kind of collection you 
want to be a part of.” Grafe came 
to Yale in 2011 and lives in North 
Guilford with her husband and 
two young sons.
In addition to overseeing 
library collections, Grafe works 
with medical school faculty. 
“They find great materials in 
their own departments and want 
to do something with them, or 
want to know more about the 
history of their own fields.” She 
and the library staff have been 
working with members of the 
Department of Surgery, help-
ing them locate materials for an 
upcoming book and exhibit on 
the department’s history. “By 
going back 20, 30, or 40 years, 
you can get to understand how 
a field has changed,” Grafe said, 
“and why it is the way it is now.”
Digitization of the library’s 
collections is another impor-
tant piece of Grafe’s work. “Our 
goal is to make our collections 
widely available to everybody. 
That’s why we digitize; we want 
the collections to be used.” The 
library also offers alumni the 
chance to digitize their own 
medical school theses and add 
their own work as Yale students 
to the online archives.
Though online access is 
vital, nothing, Grafe noted, can 
replace seeing the collections in 
person. “A digital image gives 
you a snapshot, but if you actu-
ally come to see the physical 
piece, you end up understand-
ing more about it; it gener-
ates new questions.” And, she 











“As far back as I can remember,” 
says McNeer, “I thought that 
research and science were the 
coolest things in the world.” Her 
parents, chemists who came 
from Bangladesh and now work 
at Kodak and 3M in Minnesota, 
encouraged her with chemistry 
and electronics kits. 
In January, McNeer garnered 
yet another honor. Forbes mag-
azine included the 27 year old 
in its 2015 list of 30 under 30 in 
Science & Healthcare, which 
recognizes young people with 
a record of achievement and 
promise. Soon after, McNeer 
spoke with Yale Medicine.
  Who is Nicole McNeer 
 and how does she  
  win so many awards?
Nicole McNeer, a recent 
graduate of the M.D./Ph.D. 
Program, was included  
in Forbes magazine’s 2015  
list of 30 under 30 in  
Science & Healthcare, 
which recognizes rising 
stars in the field.
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OV E R T H E PA S T T WO DE C A DE S only a handful of M.D./
Ph.D. students have completed the program in six years 
(the average is seven or eight). Among them is Nicole 
McNeer, M.D. ’14, Ph.D. ’14, whose career path straddles 
pediatrics and biomedical engineering. While she was 
fast-tracking through the program, she also earned three 
prestigious awards—for the med school graduate who 
best exemplifies the qualities of a pediatrician; the most 
outstanding dissertation by an M.D./Ph.D. student; and 
exceptional achievement in engineering research. 
When did you become  
interested in biomedical 
engineering? I had always 
been a math and physics 
nerd. When I was think- 
ing about doing an M.D./
Ph.D. program, getting  
the clinical and research 
experience, I wanted to  
try and use my math 
and physics background. 
Biomedical engineering 
seemed like a good fit.
What was the subject of 
your thesis? My research is 
focused on site-specific gene 
editing. That’s like taking 
a little piece of whiteout 
to the instruction manual, 
getting rid of the one- or 
two-letter typo that you 
have, and replacing it with 
the correct letters. There 
are several ways of doing 
this. I have been using syn-
thetic small molecules that 
are similar to DNA. Instead 
of the regular sugar type 
of backbone that DNA has, 
they have a protein type 
of backbone that binds 
to the DNA in the cell. It 
makes it look like there’s a 
lesion in the cell, which the 
cell wants to fix. The cell 
brings in its own correc-
tion machinery, and if you 
include a template with the 
sequence that you want, in 
some cases you’re lucky and 
the cell uses your sequence 
as the correct one. Most of 
my thesis focused on deliv-
ery of these small molecules 
using nanoparticles. The 
second part of my thesis was 
about applying this tech-
nology to editing the gene 
responsible for cystic fibro-
sis. It’s caused by a single 
gene defect, so it was a very 
amenable target for this 
type of technology.
How did you choose pedi-
atrics? I knew I would do 
something that had to do 
with hematology, and I had 
done some rotations in adult 
hematology and oncology, 
which was interesting.  
I really enjoyed my rotations  
in pediatric hematology  
and oncology. I liked work-
ing with families and I liked 
how pediatric oncology 
is set up from a research 
standpoint.
You’re also known around 
campus as a member 
of the Yale Belly Dance 
Society. My sister, who 
went to Harvard with me, 
convinced me to take an 
introductory course. I’d never 
done any other type of dance, 
but I found the class really 
fun. When I came to Yale, I 
tried out for the Yale Belly 
Dance Society, practiced 
very hard, and got in. I have 
taken a break from the group 
because of the demands of 
internship. Dancing, dressing 
up, and seeing friends have 
all gone by the wayside.
How are you juggling 
your internship and 
research? For the past few 
months my research has 
been mostly writing and 
paper revisions—stuff I can 
do wherever I am. I’ll have 
my computer with me, and 
when I have a moment I’ll 
work on writing, or editing, 
or data analysis. There are 
a number of people who are 
continuing various aspects 
of the projects I’d been 
working on. It has been 
really cool to see the proj-
ects branch out in different 
directions.
How did you meet your 
husband, James McNeer?  
It was my freshman year 
at Harvard, and he was a 
sophomore. He was look-
ing on Facebook for a girl 
who was interested in video 
games. We played StarCraft 
against each other; then we 
started dating. Since college 
he’s been working at a small 
hedge fund.
We got married five years 
ago. We had his pastor from 
Massachusetts and one of 
my uncles, who was train-
ing as an imam, preside over 
the wedding, with readings 
from the Koran and the 





watch a short film about  
Nicole McNeer at  
youtube.com/YaleMedicine
Bible. I think the audience 
was confused about when 
we were married because 
there were 10 different 
times when they said “you 
are married” in multiple 
languages.
How did you get nominated 
for 30 under 30? A friend 
who was in Forbes’ 30 
under 30 last year nomi-
nated me, and Forbes asked 
for information about me, 
from me and other people. 
I am not sure who all the 
other people were. It was a 
little bit embarrassing. This 
type of subjective award is 
about 5 percent what you 
do and 95 percent luck and 
who you know and hav-
ing someone nominate you. 
Within Yale there are a lot 
of people who are equally 
qualified, but it was an 
honor to be lucky enough to 
be picked for this prize.
What are your career goals? 
My ideal job would be as a 
pediatric physician/scientist 
at an academic institution; 
to have my own lab; and 
also my own clinical prac-
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 Lifestyle strategies 
and alternative medicine 
When he returned to his 
native Colorado 20 years ago 
to treat people with multiple 
sclerosis, Allen C. Bowling, 
M.D. ’88, Ph.D. ’88, believed 
he was well prepared. After 
earning a medical degree and 
a doctorate in pharmacol-
ogy at Yale, he completed his 
neurology residency at the 
University of California, San 
Francisco, and spent three 
years as a fellow at Harvard.
“I was thinking, ‘Wow! 
I have such a great toolbox 
for doing clinical practice at 
a high level.’ ” Before long, 
however, Bowling recog-
nized gaps in his knowledge. 
“There’s so much I don’t know, 
so much I didn’t get, in more 
than a decade of training.”
This realization grew out 
of the nature of multiple 
sclerosis (MS): this disease of 
the central nervous system 
is incurable and unpredict-
able and causes a constella-
tion of symptoms. Although 
his patients generally took 
conventional medications for 
MS, Bowling discovered that 
most were interested in how 
such lifestyle issues as diet 
and exercise affect the disease. 
More than half pursued strat-
egies not dreamed of in the 
medical school curriculum: 
reflexology, removal of dental 
fillings, marijuana, magnets, 
pressurized oxygen, and 
prayer. However, at that  
time, there were not any reli-
able sources of MS-specific 
information in these areas.  
“I realized that the quality of 
MS care could be improved 
by providing objective infor-
mation about the safety and 
efficacy of these lifestyle and 
unconventional approaches 
to people with MS and also to 
health professionals.
“My patients were 
immersed in these therapies 
that clearly were important 
to them—whether there was 
evidence that they worked 
or not.” Even physicians and 
scientists who were patients 
used unconventional thera-
pies and were interested in 
lifestyle approaches, said 
Bowling, who runs an MS 
practice affiliated with 
the Colorado Neurological 
Institute and is a clinical 
professor of neurology at the 
University of Colorado.
Bowling set out to evaluate 
these unconventional and life-
style strategies. His approach 
is to critically review articles 
on a topic related to lifestyle 
or alternative medicine and 
distill them into a form that’s 
user-friendly for clinicians 
and people with MS, he said.
The result is Optimal 
Health with Multiple Sclerosis: 
A Guide to Integrating Life-
style, Alternative, and 
Conventional Medicine.  
For each of the main manifes-
tations of MS, the book briefly 
describes potential therapies 
and lifestyle modifications. 
Under “walking prob-
lems,” Bowling mentions 
the standard medications 
and then lists 10 other “pos-
sibly effective lifestyle and 
unconventional therapies,” 
including cooling, tai chi, and 
therapeutic horseback rid-
ing. Much of the book is given 
over to Bowling’s elaboration 
on 49 approaches from acu-
puncture to yoga. For each, 
Bowling discusses effective-
ness, possible interactions 
with standard care, hazards, 
and side effects. He cites stud-
ies and recommends further 
reading. Lifestyle, alternative, 
and conventional medicine 
strategies are integrated into a 
seven-step approach that may 
be easily followed by patients 
and professionals.
“I encourage my patients 
to explore things and extract 
what’s helpful to them,” said 
Bowling. He has tried much 
of what his patients pur-
sue, both to understand his 
patients’ experiences and  
for his own well-being.  
For instance, he now eats 
a vegetarian diet on week-
days and has worked to 
understand his psychologi-
cal makeup, aided by “a few 
decades of free psycho-
therapy at home” thanks to 
his psychologist-wife, Diana 
S. Bowling, Ph.D.
Bowling provides information  
about lifestyle and unconven- 
tional therapies on his website,  
neurologycare.net/CAM
  Yale M.D./Ph.D. takes unconventional  
 path to develop a new paradigm of care
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book review
“PRO F E S S O R DU M B L E D O R E” (aka Richard Belitsky, M.D., HS ’82, FW ’83, deputy 
dean for education) came to the School of Medicine in January to introduce a  
traveling exhibit created by the National Library of Medicine (NLM). “Harry 
Potter’s World: Renaissance Science, Magic, and Medicine” uses the seven books 
about the boy magician as a launching pad for an exploration of science. The magic 
in the books is based in part, says the NLM, on Renaissance traditions—alchemy, 
astrology, and natural philosophy—that had a role in developing Western science. 
Middle and elementary school students enjoyed a scavenger hunt, which had  
them scouring the library for the initials of someone wearing a wizard’s hat,  
a paw print from Finn the Therapy Dog, stickers in the library’s brain room, and 
other items. Jun Wan, a visiting research scientist, donned Harry Potter glasses  
for a photo with “Professor Dumbledore.”
“If I can conjure up just a little bit of magic and wizardry,” said Belitsky, the 
Harold W. Jockers Associate Professor of Medical Education, “I’m going to  
try to make myself disappear and hope that all of you forever forget this moment.”
—John Curtis
All welcome Dumbledore!!!
end note
